Stratification criteria	Description

Physician Integrated Network (PIN) [30]	A Manitoba Health primary care renewal initiative that focuses on fee-for-service (FFS) physician groups.

Its goal is to facilitate systemic improvements in the delivery of primary care.

Objectives:

● To improve access to primary care

● To improve Primary Care Providers’ access to and use of information

● To improve the work life for all primary care providers

 	● To demonstrate high quality primary care with a specific focus on Chronic Disease Management

Uniting Primary Care and Oncology Network (UPCON)[31]	A collaborative partnership between Winnipeg family practice clinics/primary health care centres and CancerCare Manitoba (CCMB) that is dedicated to promoting and supporting the shared care of the cancer patient.

Stratification criteria	Description

Physician Inte	A Manitoba Health primary care renewal initiative that focuses on fee-for-service (FFS) physician groups.

Its goal is to facilitate systemic improvements in the delivery of primary care.

Objectives:

● To

Stratification criteria	Description

grated Network (PIN) [30]	 improve access to primary care

● To improve Primary Care Providers’ access to and use of information

● To improve the work life for all primary care providers

	● To demonstrate high quality primary care with a specific focus on Chronic Disease Management

Uniting Primary Care and Oncology Network (UPCON)[31]	A collaborative partnership between Winnipeg family practice clinics/primary health care centres and CancerCare Manitoba (CCMB) that is dedicated to promoting and supporting the shared care of the cancer patient.


Tissue sample	Type of core	No. of cores in TMA blocks

Control Normal Samples	Normal	119

DCIS	Normal in DCIS	12

DCIS pure lesion	54

IDC	Normal in IDC	61

DCIS in IDC	39

IDC pure lesion	120

DCIS	DCIS pure lesion	54

IDC	Normal in IDC	61

DCIS in IDC	39

IDC pure lesion	120


Cancer	Accession number

Breast cancer	GSE42568

GSE15852

Lung cancer	E-MEXP-231

GSE19804

Prostate cancer	GSE6956

GSE6919

Hepatocellular carcinoma	GSE14323

GSE6764


 	Dry mucus membranes (eyes/mouth)	Lighter/uneasy sleep	Heavier sleep	Sleepiness at daytime	Increased fatigue	Dizziness

Patient #1	x	x	 	 	x

Patient #2	x	 	 	x

Patient #3	x	x

Patient #4	x	 	 	 	 	x

Patient #5	x	 	x

	Dry mucus membranes (eyes/mouth)	Lighter/uneasy sleep	Heavier sleep	Sleepiness at daytime	Increased fatigue

Patient #1	x	x			x

Patient #2	x			x

Patient #3	x	x

Patient #4	x

Patient #5	x		x


	Surgery group	Packing group	P

Re-bleeding	0	4	0.001

Discomfort after the treatment	2.4±1.4	7.6±1.0	0.001

Adhesion of nasal cavity	2	7	0.007


Gene	Primer sequences

hsa-miR-155	RT	5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCACCCCT-3′

Forward	5′- CTTAATGCTAATCGTGAT -3′

Reverse	5′- GAG CAG GCT GGA GAA -3′

hsa-miR-146a	RT	5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCAACCCA -3′

Forward	5′- CTGAGAACTGAATTCCA -3′

Reverse	5′- GAG CAG GCT GGA GAA -3′

U6	RT	5′-CGCTTCACGAATTTGCGTGTCAT -3′

Forward	5′- CTCGCTTCGGCAGCACATA -3′

Reverse	5′- CGCTTCACGAATTTGCGTG -3′

TGF-β1	Forward	5′- CCAACTATTGCTTCAGCTCCA -3′

Reverse	5′- GTGTCCAGGCTCCAAATGT -3′

TNF-α	Forward	5′- CCCAGGGACCTCTCTCTAATCA -3′

Reverse	5′- AGCTGCCCCTCAGCTTGAG -3′

GAPDH	Forward	5′-CCCCTTCATTGACCTCAACTAC-3′

 	Reverse	5′-GATGACAAGCTTCCCGTTCTC-3′

hsa-miR-155	Forward	5′- CTTAATGCTAATCGTGAT -3′

Reverse	5′- GAG CAG GCT GGA GAA -3′

hsa-miR-146a	RT	5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCAACCCA -3′

Forward	5′- CTGAGAACTGAATTCCA -3′

Reverse	5′- GAG CAG GCT GGA GAA -3′

U6	RT	5′-CGCTTCACGAATTTGCGTGTCAT -3′

Forward	5′- CTCGCTTCGGCAGCACATA -3′

Reverse	5′- CGCTTCACGAATTTGCGTG -3′

TGF-β1	Forward	5′- CCAACTATTGCTTCAGCTCCA -3′

Reverse	5′- GTGTCCAGGCTCCAAATGT -3′

TNF-α	Forward	5′- CCCAGGGACCTCTCTCTAATCA -3′

Reverse	5′- AGCTGCCCCTCAGCTTGAG -3′

GAPDH	Forward	5′-CCCCTTCATTGACCTCAACTAC-3′

	Reverse	5′-GATGACAAGCTTCCCGTTCTC-3′


Gene_symbol	Description	Log2 Ratio (A253-5/A253-0)	P value

MAPK10	mitogen-activated protein kinase 10	−1.1440	0.000264947

AKT1	v-akt murine thymoma viral oncogene homolog 1	1.1076	0.014492851

PDGFB	platelet-derived growth factor beta polypeptide	1.0834	6.23066E-05

BIRC3	baculoviral IAP repeat containing 3	1.0176	0.001517394

PGF	placental growth factor	−1.0496	0.025969431

COL4A1	collagen, type IV, alpha 1	2.1236	1.58011E-20

FN1	fibronectin 1	3.6490	3.35978E-24

THBS1	thrombospondin 1	1.0290	0.000135356

FLT1	fms-related tyrosine kinase 1	1.2325	0.025381832

RASGRF1	Ras protein-specific guanine nucleotide-releasing factor 1	1.7221	1.11117E-05

CCND2	cyclin D2	2.3619	8.02038E-19

COL5A2	collagen, type V, alpha 2	1.2806	0.030736616

TNC	tenascin C	1.6496	9.83873E-07

PARVA	parvin, alpha	1.2195	9.20291E-07


Item	Mean	SD	Range	95% CI

1. I have a desire to succeed	4.6	0.62	1–5	4.56; 4.72

2. I have my own plan for how to stay or become well	3.9	0.92	1–5	3.80; 4.05

3. I have goals in life that I want to reach	4.2	0.90	1–5	4.08; 4.32

4. I believe that I can meet my current personal goals	3.7	0.98	1–5	3.59; 3.85

5. I have a purpose in life	3.8	0.94	1–5	3.72; 3.97

6. Even when I don’t care about myself, other people do	4.1	0.83	1–5	4.0; 4.21

7. Fear doesn’t stop me from living the way I want to	3.1	1.30	1–5	2.90; 3.25

8. I can handle what happens in my life	3.3	1.02	1–5	3.20; 3.47

9. I like myself	3.2	1.20	1–5	2.99; 3.31

10. If people really knew me, they would like me	3.7	0.84	1–5	3.60; 3.82

11. I have an idea of who I want to become	3.5	1.05	1–5	3.40; 3.67

12. Something good will eventually happen	4.0	0.81	1–5	3.93; 4.14

13. I’m hopeful about my future	3.9	0.99	1–5	3.72; 3.97

14. I continue to have new interests	3.7	1.09	1–5	3.57; 3.86

15. Coping with my mental illness is no longer the main focus of my life	3.1	1.23	1–5	2.98; 3.30

16. My symptoms interfere less and less with my life	3.4	1.20	1–5	3,25; 3.54

17. My symptoms seem to be a problem for shorter periods of time each time they occur	3.5	1.13	1–5	3.32; 3.61

18. I know when to ask for help	3.9	1.06	1–5	3.78; 4.05

19. I am willing to ask for help	4.1	0.92	1–5	4.01; 4.25

20. I ask for help when I need it	3.8	1.08	1–5	3.68; 3.96

21. I can handle stress	3.0	1.14	1–5	2.88; 3.18

22. I have people I can count on	4.3	0.78	1–5	4.18; 4.38

23. Even when I don’t believe in myself, other people do	4.0	0.87	1–5	3.88; 4.10

24. It is important to have a variety of friends	3.5	1.40	1–5	3.31; 3.67

Summary scales

Personal confidence and hope (mean of items 7, 8, 9, 10, 11, 12, 13, 14 & 21)	3.5	0.68	1.67–5	3.40; 3.58

Willingness to ask for help (mean of items 18, 19 & 20)	4.0	0.89	1–5	3.84; 4.07

Goal and success orientation (mean of items 1, 2, 3, 4 & 5)	4.1	0.63	1.4–5	3.99; 4.15

Reliance on others (mean of items 6, 22, 23 & 24)	4.0	0.68	2–5	3.88; 4.06

Not dominated by symptoms (mean of items 15, 16 & 17)	3.3	0.95	1–5	3.21; 3.45

Total scale (mean of items)	3.7	0.56	1.92–5	3.66; 3.80

Total scale (sum of items)	89.5	13.39	46–120	87.75; 91.24

Item	Mean	SD	Range	95% CI

Reliance on others (mean of items 6, 22, 23 & 24)	4.0	0.68	2–5	3.88; 4.06

Not dominated by symptoms (mean of items 15, 16 & 17)	3.3	0.95	1–5	3.21; 3.45

Total scale (mean of items)	3.7	0.56	1.92–5	3.66; 3.80

Total scale (sum of items)	89.5	13.39	46–120	87.75; 91.24


Study design	Methods & numbers	Research instruments	Respondents

Qualitative study	*GDs: 14 (One group from each hospital)	GD guideline: semi-structured open-ended questions with probes	From district hospitals: civil surgeon, obstetrics and pediatrics consultants, anesthesiologist, nursing superintendent, and two senior staff nurses

From MCWCs: deputy director of family planning, anesthesiologist, medical officer, one nurse, and one family welfare visitor

From UHCs: upazila health and family planning officer, obstetrics and gynecology specialists, pediatrician, anesthesiologist, resident medical officer, and one nurse

**IDIs:56 (four interviews from each hospital)	IDI guideline: semi-structured open-ended questions with probes	From district hospitals, MCWCs, and UHCs: One laboratory technician/pharmacist, one ward master/nursing supervisor, one ancillary staff from the maternal or neonatal wards, and one cleaner

Quantitative study	Exit interviews: 112 (eight exit interviews from each hospital)	Structured questionnaire	Patients or their attendants from maternal, labor, and neonatal wards at district hospitals, MCWCs, and UHCs

Qualitative study	*GDs: 14 (One group from each hospital)	GD guideline: semi-structured open-ended questions with probes	From MCWCs: deputy director of family planning, anesthesiologist, medical officer, one nurse, and one family welfare visitor

From UHCs: upazila health and family planning officer, obstetrics and gynecology specialists, pediatrician, anesthesiologist, resident medical officer, and one nurse

**IDIs:56 (four interviews from each hospital)	IDI guideline: semi-structured open-ended questions with probes	From district hospitals, MCWCs, and UHCs: One laboratory technician/pharmacist, one ward master/nursing supervisor, one ancillary staff from the maternal or neonatal wards, and one cleaner

Quantitative study	Exit interviews: 112 (eight exit interviews from each hospital)	Structured questionnaire	Patients or their attendants from maternal, labor, and neonatal wards at district hospitals, MCWCs, and UHCs


Colorectal cancer characteristic	Black Mississippians	White Mississippians	Difference (Black–White)	P value

Statistically-significant health disparities

 % (Age 50+) reporting NEVER had a sigmoidoscopy or colonoscopy (average: 2006, 2008 and 2010 BRFSS)	53.2 %	41.9 %	11.3 %	<.0001

 Age-adjusted colorectal cancer incidence rate (per 100,000; 2006–2010 MCR data)	64.9	50.5	14.4	<.0001

 Age-adjusted colorectal cancer mortality rate (per 100,000; 2006–2010 MCR data)	26.2	17.5	8.8	0.0001

 CRC mortality-to-incidence rate	0.40	0.35	0.05	0.0035

No discernible differences between groups

 % Advanced stage (regional + distant disease) at initial diagnosis	52.9 %	52.3 %	0.6 %	0.7926

Colorectal cancer characteristic	Black Mississippians	White Mississippians	Difference (Black–White)

Statistically-significant health disparities

% (Age 50+) reporting NEVER had a sigmoidoscopy or colonoscopy (average: 2006, 2008 and 2010 BRFSS)	53.2 %	41.9 %	11.3 %

Age-adjusted colorectal cancer incidence rate (per 100,000; 2006–2010 MCR data)	64.9	50.5	14.4

Age-adjusted colorectal cancer mortality rate (per 100,000; 2006–2010 MCR data)	26.2	17.5	8.8

CRC mortality-to-incidence rate	0.40	0.35	0.05

No discernible differences between groups

% Advanced stage (regional + distant disease) at initial diagnosis	52.9 %	52.3 %	0.6 %

P value

Statistically-significant health disparities

<.0001

<.0001

0.0001

0.0035

No discernible differences between groups

0.7926


Database	Crops	Web link	Reference

Gramene	Grasses	http://www.gramene.org	Tello-Ruiz et al., 2016

International Rice Informatics Consortium	Rice (Oryza sativa)	http://iric.irri.org	n/a

Maize Genetics and Genomics Database	Maize (Zea mays)	http://www.maizegdb.org	Lawrence et al., 2004

SoyKB	Soybean (Glycine max)	http://soykb.org	Joshi et al., 2014

T3 Triticaceae toolbox	Wheat (Triticum aestivum), barley (Hordeum vulgare) and oat (Avena sativa)	https://triticeaetoolbox.org/	Blake et al., 2016

Wheat Information System	Wheat (Triticum aestivum)	http://wheatis.org	n/a

Database	Crops	Web link	Reference

International Rice Informatics Consortium	Rice (Oryza sativa)	http://iric.irri.org	n/a

Maize Genetics and Genomics Database	Maize (Zea mays)	http://www.maizegdb.org	Lawrence et al., 2004

SoyKB	Soybean (Glycine max)	http://soykb.org	Joshi et al., 2014

T3 Triticaceae toolbox	Wheat (Triticum aestivum), barley (Hordeum vulgare) and oat (Avena sativa)	https://triticeaetoolbox.org/	Blake et al., 2016

Wheat Information System	Wheat (Triticum aestivum)	http://wheatis.org	n/a


		Visits before	Visits after	Visitors before	Visitors after	Change visits	Change visitors

		(2 years)	(2 years)			n (%)	n (%)

Income below median	51788	225746	238731	44685	44567	12985 (5.8)	−118 (−0.3)

Income above median	51817	206358	229664	44223	45443	23306 (11.3)	1220 (2.8)


Family	Name	Local RDB	National RL rank	Main habitat	Life forms

Azollaceae	Azolla japonica	35	VU	Paddy, Ditch	perennial fern

Hydrocharitaceae	Blyxa echinosperma	42	VU	Paddy, Ditch	annual

Alismataceae	Caldesia parnassifolia	37	VU	Pond, Lake, Paddy	perennial

Compositae	Gnaphalium hypoleucum	40	VU	Forest edge	annual

Isoetaceae	Isoetes japonica	36	NT	Pond, Paddy, Ditch	perennial fern

Compositae	Ixeris chinensis subsp. strigosa	40	VU	Grassland, Roadside	perennial

Labiatae	Leonurus macranthus	39	VU	Grassland	perennial

Marsileaceae	Marsilea quadrifolia	46	VU	Paddy, Ditch	perennial fern

Pontederiaceae	Monochoria korsakowii	39	NT	Lake, River, Ditch, Paddy(fallow)	annual

Labiatae	Mosla japonica	36	NT	Roadside	annual

Najadaceae	Najas gracillima	40	NT	Pond, Paddy	annual

Menyanthaceae	Nymphoides peltata	40	NT	Lake, Pond, Paddy	perennial

Saxifragaceae	Penthorum chinense	41	NT	Swamp	perennial

Polygonaceae	Persicaria foliosa var. paludicola	36	VU	Swamp, Paddy(fallow), Pond	annual

Polygonaceae	Persicaria taquetii	36	VU	Swamp, Paddy	annual

Potamogetonaceae	Potamogeton berchtoldii	44	NT	Lake, Pond, River, Ditch	perennial

Salviniaceae	Salvinia natans	40	NT	Paddy, Ditch	annual fern

Compositae	Saussurea pulchella	39	VU	Grassland, Forest edge	annual

Sparganiaceae	Sparganium fallax	41	NT	Lake, Pond, River	perennial

Sparganiaceae	Sparganium stenophyllum	41	VU	Lake, Pond	perennial

Trapaceae	Trapa incisa	37	VU	Lake, Pond, Ditch, Paddy	annual

Lentibulariaceae	Utricularia uliginosa	43	NT	Swamp	perennial

Asclepiadaceae	Vincetoxicum pycnostelma	44	NT	Grassland	perennial

Family	Name	Local RDB	National RL rank

Azollaceae	Azolla japonica	35	VU

Hydrocharitaceae	Blyxa echinosperma	42	VU

Alismataceae	Caldesia parnassifolia	37	VU

Compositae	Gnaphalium hypoleucum	40	VU

Isoetaceae	Isoetes japonica	36	NT

Compositae	Ixeris chinensis subsp. strigosa	40	VU

Labiatae	Leonurus macranthus	39	VU

Marsileaceae	Marsilea quadrifolia	46	VU

Pontederiaceae	Monochoria korsakowii	39	NT

Labiatae	Mosla japonica	36	NT

Najadaceae	Najas gracillima	40	NT

Menyanthaceae	Nymphoides peltata	40	NT

Saxifragaceae	Penthorum chinense	41	NT

Polygonaceae	Persicaria foliosa var. paludicola	36	VU

Polygonaceae	Persicaria taquetii	36	VU

Potamogetonaceae	Potamogeton berchtoldii	44	NT

Salviniaceae	Salvinia natans	40	NT

Compositae	Saussurea pulchella	39	VU

Sparganiaceae	Sparganium fallax	41	NT

Sparganiaceae	Sparganium stenophyllum	41	VU

Trapaceae	Trapa incisa	37	VU

Lentibulariaceae	Utricularia uliginosa	43	NT

Asclepiadaceae	Vincetoxicum pycnostelma	44	NT

Main habitat	Life forms

Paddy, Ditch	perennial fern

Paddy, Ditch	annual

Pond, Lake, Paddy	perennial

Forest edge	annual

Pond, Paddy, Ditch	perennial fern

Grassland, Roadside	perennial

Grassland	perennial

Paddy, Ditch	perennial fern

Lake, River, Ditch, Paddy(fallow)	annual

Roadside	annual

Pond, Paddy	annual

Lake, Pond, Paddy	perennial

Swamp	perennial

Swamp, Paddy(fallow), Pond	annual

Swamp, Paddy	annual

Lake, Pond, River, Ditch	perennial

Paddy, Ditch	annual fern

Grassland, Forest edge	annual

Lake, Pond, River	perennial

Lake, Pond	perennial

Lake, Pond, Ditch, Paddy	annual

Swamp	perennial

Grassland	perennial


Rat number	Control group	Cyanoacrylate group

Researcher 1	Researcher 2	Researcher 1	Researcher 2

1	0	0	1	1

2	0	0	0	0

3	2	2	1	2

4	2	2	2	2

5	1	1	2	2

6	2	2	1	1

7	0	0	1	2

8	2	2	2	1

Rat number	Control group	Cyanoacrylate group

Researcher 1	Researcher 2	Researcher 1	Researcher 2

1	0	0	1	1

	0			0

Rat number	Control group	Cyanoacrylate group

Researcher 1	Researcher 2	Researcher 1	Researcher 2

2		0	0

3	2	2	1	2

4	2	2	2	2

5	1	1	2	2

6	2	2	1	1

7	0	0	1	2

8	2	2	2	1


SSP no.	Accession no.	Protein Description	Mass in kDa (experiment/predicted)	pI (experiment/predicted)	Sequence coverage (%)	Number of peptides matched	Mowse score	Error (ppm)

pH 4–7

2120	6065880	Heterogeneous nuclear ribonucleoprotein H2	38.43/49.52	3.96/5.89	46	15	171	14

3609	515634	Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial precursor	54.55/52.75	5.30/5.94	46	15	170	17

3617	4826760	Heterogeneous nuclear ribonucleoprotein F	57.18/45.87	5.25/5.38	31	8	88	9

4422	57093855	Similar to heterogeneous nuclear ribonucleoprotein H (hnRNP H)	38.53/46.38	4.46/6.61	43	12	131	6

pH 6–11

7818	8574295	Voltage-dependent anion channel 2	20.00/31.65	9.43/7.49	41	8	88	18

7821	21619296	Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1	20.00/34.95	9.40/8.37	23	7	72	9


	Control (n = 20)	Imagery (n = 20)

	mean ± SD	mean ± SD

Did you ....

... feel your imagery improved? (1: not at all, 7: considerably)	5.45 ± 1.10	5.80 ± 0.77

... image as instructed and practiced? **(1: not at all, 7: exactly)	5.65 ± 0.67	6.20 ± 0.70

... notice any movement in the non-dominant hand? (1:not at all, 7: full grasping)	3.70 ± 1.08	3.32 ± 1.25

How ...

... easy to image the feelings? (1: very hard, 7: very easy)	5.00 ± 1.41	5.20 ± 1.01

... clear and vivid was the imagery? (1: no image at all, 7: perfectly clear/vivid)	5.40 ± 0.94	5.45 ± 0.76

	Control (n = 20)	Imagery (n = 20)

	mean ± SD	mean ± SD

... image as instructed and practiced? **(1: not at all, 7: exactly)	5.65 ± 0.67	6.20 ± 0.70

... notice any movement in the non-dominant hand? (1:not at all, 7: full grasping)	3.70 ± 1.08	3.32 ± 1.25

How ...

... easy to image the feelings? (1: very hard, 7: very easy)	5.00 ± 1.41	5.20 ± 1.01

... clear and vivid was the imagery? (1: no image at all, 7: perfectly clear/vivid)	5.40 ± 0.94	5.45 ± 0.76


Parameter	Activity rate	Time (%) in novel	Crossing/min

VEH controls	3.79 ± 0.21	79.7 ± 1.09	2.55 ± 0.26

DAT-i mice	4.10 ± 0.22	78.6 ± 1.75	2.98 ± 0.33


Primers	Sequence (5′-3′)

Primers for gene disruption and complementation

 LwblA-F	AAGCTTTCGGGTACGCCATCTCGTA

 LwblA-R	TCTAGAGCTGCTCCCTGAACGAACA

 RwblA-F	GGATCCACGACGAGGTGTACGAGAAC

 RwblA-R	GATATCTGACGCTGCTGGAGGAGAT

 Kan-F	TCTAGAGATCCCCTGGATACCGCTCG

 Kan-R	GGATCCGTACCCGAACCCCAGAGTC

 wblAJ-F	AACTGGCGGCGGTGAATA

 wblAJ-R	ACGGACGGAGCACATATAGG

 CwblA-F	GGATCCGCCTGAACGGACGGAGCACATA

 CwblA-R	TCTAGAAGCACACTGACACCGAGGAACTTGGC

Primers for qRT-PCR

 RTsanG-F	GGCGTACACAGCTCAAGAGC

 RTsanG-R	AATTCGTCGATGAGCTGATC

 RTsanN-F	AGATCATGCGCTCGGACTGT

 RTsanN-R	TGGCGTGCAGGATCGGTA

 RTsanO-F	ACTGCGATCCGTGGTCAA

 RTsanO-R	TGTACTCCAGGCACTCCC

 RTsanF-F	CGGCGCTGGAGGAACGTAC

 RTsanF-R	GGGTGTAGAGGCCGATGCT

 RThrdB-F	GCTGGCCAAGGAACTCGACAT

 RThrdB-R	CGAAGCGCATGGAGACGACG

Primers	Sequence (5′-3′)

CwblA-R	TCTAGAAGCACACTGACACCGAGGAACTTGGC

Primers for qRT-PCR

RTsanG-F	GGCGTACACAGCTCAAGAGC

RTsanG-R	AATTCGTCGATGAGCTGATC

RTsanN-F	AGATCATGCGCTCGGACTGT

RTsanN-R	TGGCGTGCAGGATCGGTA

RTsanO-F	ACTGCGATCCGTGGTCAA

RTsanO-R	TGTACTCCAGGCACTCCC

RTsanF-F	CGGCGCTGGAGGAACGTAC

RTsanF-R	GGGTGTAGAGGCCGATGCT

RThrdB-F	GCTGGCCAAGGAACTCGACAT

RThrdB-R	CGAAGCGCATGGAGACGACG


Gene Locus ID	Gene description	Normalized Fold (Log2)

P	HC	PHC

GSVIVT00016386001	Vitis vinifera respiratory burst oxidase homolog protein E (VvRBOHE)	0.30 ± 0.21	1.11 ± 0.18	−1.22 ± 0.06

GSVIVT00002525001	Vitis vinifera respiratory burst oxidase homolog protein A (VvRBOHA)	−0.64 ± 0.06	−1.53 ± 0.29	−1.96 ± 0.16

GSVIVT00031598001	Vitis vinifera peroxidase 72 (VvPOD72)	1.59 ± 0.77	2.09 ± 1.18	4.19 ± 0.18

GSVIVT00031723001	Vitis vinifera peroxidase 12 (VvPOD12)	−0.79 ± 0.05	−0.74 ± 0.25	−1.71 ± 0.13

GSVIVT00020782001	Vitis vinifera alpha-dioxygenase 1 (VvDOX1)	1.83 ± 1.16	2.82 ± 0.55	0.13 ± 0.25

GSVIVT00001920001	Vitis vinifera glutathione peroxidase 2 (VvGPX2)	0.34 ± 0.39	0.28 ± 0.45	1.10 ± 0.54

GSVIVT00004080001	Vitis vinifera catalase isozyme 1-like (VvCAT1)	−0.35 ± 0.17	−1.52 ± 0.02	−1.57 ± 0.15

GSVIVT00036747001	Vitis vinifera cytosolic ascorbate peroxidase (VvAPX3)	−0.47 ± 0.24	−1.05 ± 0.09	−1.75 ± 0.04

GSVIVT00007083001	Vitis vinifera superoxide dismutase [Fe] 3, chloroplastic (VvFSD3)	0.40 ± 0.17	0.17 ± 0.10	1.82 ± 0.11

GSVIVT00014163001	Vitis vinifera superoxide dismutase [Fe], chloroplastic (VvFSD)	0.50 ± 0.13	0.33 ± 0.22	−1.60 ± 0.17

GSVIVT00003173001	Vitis vinifera alternative oxidase 2, mitochondrial (VvAOX2)	0.44 ± 0.16	2.43 ± 0.37	1.07 ± 0.18

GSVIVT00036443001	Vitis vinifera hemoglobin-2 (VvHB2)	−0.52 ± 0.43	4.41 ± 0.34	3.08 ± 0.43


Background characteristics	Infants starting the intervention (N = 86)	Infants completing 3 weeks (N = 81)

	Acupuncture group (n = 46)	Control group (n = 40)	Acupuncture group (n = 43)	Control group (n = 38)

Firstborn, n (%)	22 (48)	22 (55)	21 (48)	21 (55)

Gender, female, n (%)	22 (48)	19 (48)	21 (50)	19 (50)

Gestational age, weeks. Mean (SD)	39.2 (1.5)	39.5 (1.3)	39.3 (1.4)	39.5 (1.3)

Age when colic started, weeks. Mean (SD)	1.9 (1.3)	1.5 (1.0)	2 (1.3)	1.5 (1)

Age at inclusion, weeks. Mean (SD)	5.0 (1.9)	5.3 (1.7)	5.1 (1.9)	5.2 (1.6)

Solely breastfed, n (%)	35 (76)	26 (65)	32 (74)	25 (66)

Having a parent and/or sibling with food intolerance/allergy, n (%)	17 (37)	18 (45)	15 (35)	17 (45)

Having a parent and/or sibling who had had infantile colic, n (%)	29 (63)	23 (58)	25 (58)	20 (53)

Have tried simeticone, n (%)	43 (93)	37 (92)	40 (93)	35 (92)

With no effect, n (%)	28 (61)	25 (63)	26 (60)	23 (61)

With uncertain effect, n (%)	15 (33)	12 (30)	14 (33)	12 (32)

Have tried lactobacillus reuteri, Semper Magdroppar ®, n (%)	6 (13)	7 (18)	6 (14)	6 (16)

With no effect, n (%)	4 (9)	7 (18)	4 (9)	6 (16)

With uncertain effect, n (%)	2 (4)	0 (0)	2 (5)	0 (0)

Have tried a diet free from cow'rotein without effect, n (%)	33 (72)	32 (80)	31 (72)	30 (79)

Changed to this diet during the intervention weeks, n (%)	1 (2)	1 (3)	1 (2)	1 (3)

Not ensured if this diet is tried, n (%)	12 (26)	7 (18)	11 (26)	7 (18)

Received antibiotics, either through mother's medication or by own intake, n (%)	14 (30)	10 (25)	12 (28)	9 (24)


	1995	2001	Change %

Admitted patients/doctor/year	101	87	-13.9

Admitted patients/nurse/year	24	22	-8.3

Admitted patients/office staff/year	106	83	-21.7

In-hospital patients at all hours	813	793	-2.5

In-hospital patients at all hours/doctor	2,2	1,6	-28.3

In-hospital patients at all hours/nurse	0.5	0,39	-20.0

In-hospital patients at all hours/office staff	2,3	1.5	-34.8

Deliveries/midwife/year	57	44	-22.8

Out-patients consultations/doctor/year	629	530	-15.7

Out-patients consultations/nurse/year	147	134	-8.8

Out-patients consultations/office staff/year	656	503	-23.3

Surgical procedures/doctor/year – total*	160	128	-20.0

 General surgery	151	134	-11.4

 Orthopedic surgery	189	155	-18.0

 Neurosurgery	98	100	+2.0

 Otorhinolaryngology	177	125	-29.4

 Ophthalmology	135	152	+12.6

 Gynecology	109	71	-34.9

Anesthetized patients/anesthesiologist/year§	661	534	-19.2

Hours with anesthesia/anesthesiologist/year	1 322	1 148	-13.2

Imaging procedures/radiologist/year	7 003	5 198	-25.8

Imaging procedures/radiology technician/year	2 436	2 077	-14.7

Lab test and procedures/technologist/year#	15 981	15 256	-4.5

	1995	2001	Change %

Admitted patients/doctor/year	101	87	-13.9

Admitted patients/nurse/year	24	22	-8.3

Admitted patients/office staff/year	106	83	-21.7

In-hospital patients at all hours	813	793	-2.5

In-hospital patients at all hours/doctor	2,2	1,6	-28.3

In-hospital patients at all hours/nurse	0.5	0,39	-20.0

In-hospital patients at all hours/office staff	2,3	1.5	-34.8

Deliveries/midwife/year	57	44	-22.8

Out-patients consultations/doctor/year	629	530	-15.7

Out-patients consultations/nurse/year	147	134	-8.8

Out-patients consultations/office staff/year	656	503	-23.3

Surgical procedures/doctor/year – total*	160	128	-20.0

General		13	-

 surgery	151	4	11.4

Orthopedic surgery	189	155	-18.0

Neurosurgery	98	100	+2.0

Otorhinolaryngology	177	125	-29.4

Ophthalmology	135	152	+12.6

Gynecology	109	71	-34.9

Anesthetized patients/anesthesiologist/year§	661	534	-19.2

Hours with anesthesia/anesthesiologist/year	1 322	1 148	-13.2

Imaging procedures/radiologist/year	7 003	5 198	-25.8

Imaging procedures/radiology technician/year	2 436	2 077	-14.7

Lab test and procedures/technologist/year#	15 981	15 256	-4.5


Drug	UDS proportion (95% CI)*	CASI

Past 7 days	Past 6 months	Lifetime

Any d	53.5 	42.	5	92.4


Outcome	P value

Arthralgia	0.390

Bone pain	0.608

Back pain	0.744

Pain in extremity	0.056

Myalgia	0.794

LS BMD 12 months (normal at baseline-ZOL trials)	0.0003

LS BMD 12 months (osteopenic at baseline-ZOL trials)	0.296

LS BMD 12 months (residronate and ibandronate trials)	0.345

Outcome	P value

LS BMD 12 months (normal at baseline-ZOL trials)	0.0003

LS BMD 12 months (osteopenic at baseline-ZOL trials)	0.296

LS BMD 12 months (residronate and ibandronate trials)	0.345


Categories	First-line treatment (XELOX plus bevacizumab)	Second-line treatment (FOLFIRI)	Clinical Support	Death

R$	%	R$	%	R$	%	R$	%


Age group	HIV-positive children n = 123	HIV-uninfected children n = 192

Months	Male	Female	Male

0–5.9	1	2	4

6–11.9	15	8	21

12–23.9	36	21	66

24–35.9	17	8	19

36–47.9	4	4	6

48–59.9	2	5	5

Total	75	48	121

HIV-uninfected children n = 192	Total

Female

4	11

14	58

37	160

6	50

6	20

4	16

71	315


Factor	Cronbach's alpha	Number of items

Privacy	.756	3

Culture	.926	3

Attitude toward telemedicine 	.755	3

Benefit	.729	5

Connectivity 	.794	3

IT capability	.706	3

Compatibility 	.763	3

Data warehouse	.749	3

Technical support	.787	3

Top management support	.706	3

Cost	.728	4

Policy	.815	3

Upper-level leadership	.818	3

Factor	Cronbach's alpha	Number of items

Upper-level leadership	.818	3


 	Patients (n = 38)	Controls (n = 23)

Median age (range) years	37 (18 to 50)	36 (24 to 49)

Sex distribution	26 F/12 M	15 F/7 M

CIS/MS at 12 months	19/19	—

Median lesion volume (range) mL	0.54 (0 to 38.1)	—

Median number of new lesions 	1 (0 to 4)	—

Median OR lesion volume (range) mL	0.06 (0 to 21.3)	—


Construct	Measure	Administration

Primary Outcome measure

Symptom Severity	Irritable Bowel Symptom Severity Scale	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Secondary Outcome measures

Symptom frequency	Daily Symptom Diary	Daily during the intervention and for 2 weeks post

IBS-related anxiety	Visceral Sensitivity Index	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Economic impact of IBS	The Work Productivity and Activity Impairment for IBS (WPAI: IBS)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Co-Morbid Symptoms	Recent Physical Symptoms Questionnaire (RPSQ)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

General psychological distress	Brief Symptom Inventory (BSI)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Anger and its expression	The State-trait Anger Expression Inventory (STAXI)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Maladaptive coping methods	Coping Strategies Questionnaire (CSQ)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Quality of life specific to IBS	IBS-QOL	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Effect modification measures

Expectancy of success of intervention	Borkovec and Nau credibility scales	Prior to second session

Catalogue of distressing prior events	Family Inventory of Life Events (FILE)	Pre intervention only

Demographics	Age, race, education, marital status, income	Pre intervention only

Process measures

Measure of mindfulness: Multiple constructs	Five Facet Mindfulness Questionnaire (FFMQ)	Pre, 2 wk, 6 mo, 12 mo post

Measure of mindfulness: Acceptance construct	Toronto Mindfulness Scale	Pre, 2 wk, 6 mo, 12 mo post


Organizations	Carbohydrates	Fiber	Protein	Fat

American Diabetes Association (ADA)	50–60%	Not specified	10–15%	30–35%

The British Diabetic Association/Diabetes UK	45–60%	<30 g/day	30–35%	<35%

European Association for the Study of Diabetes (EASD)	45–60%	Increase fiber with low-GI food	10–20%	35%

The Canadian Diabetes Association (CDA)	50–60%	25–35 g/day	11%	30%

Japan	60%	1 fruit + 400 g vegetables	15–20%	20–25%

South Africa	50–60%	40 g/day	12–30%	≤30%

India	>65%	40 g/day	12–20%	<21%

Mediterranean diet	40–42%	~23 g/day	~16%	40–42%


Gene	Reagent Sequences

MIP-1α	F; AGCTGACACCCCGACTGC

	R; GTCAACGATGAATTGGCGTG

	P; TGCTGCTTCTCCTACAGCCGGAAGAT

MIP-1β	F; AGCTCTGCGTGTCTGCCC T

	R; GCTGAGAACCCTAGAGCACA

	P; TCTCCT CTTGCTCGTGGCTGCCTT

TNFα	F; TCCAGGCGGTGCCTATGT

	R; GAGCGTGGTGGCCCC

	P; TCAGCCTCTTCTCATTCCTGCTTGTGG

iNOS	F; TGATGTCCGAAGCAAACATCA

	R; TGTGGCTCCCATGTTGCAT

	P; TTCAGATCCCGAAACGCTTCACTTCC

IL-1β	F; TTGGGCCTCAAAGGAAAGAAT

	R; TCTCCAGCTGCAGGGTGG

	P; TATACCTGTCCTGTGTAATGAAAGACGGCA CA

IκBα	F; CGGAGGACGGAGGACTCGTT

	R; ACTTCCATGGTCAGCGGCT

	P; TGCACTTGGCAATCATCCACGAAGA

FasL	F; TACCACCGCCATCACAACC

	R; TTTGTGTTGTGGTCCTTCTTCTTTAG

	P; CTCCCACTGCCGCCACTGACC

GFAP	F; GGAGCTCAATGACCGCTTTG

	R; AGCGCCTTGTTTTGCTGCTC

	P; CAGCTACATCGAGAAGGTTCG

RANTES	F; TCTTGCAGTCGTGTTTGTCAC

	R; TCTTGAACCCACTTCTTCTCT

	P; AGGAACCGCCAAGTGTGTGC

CCR5	F; GGAATGACACACTGCTGCCTAA

	R; GAACACTGAGAGATAACTCCGGAAC

	P; CCCTGTCATCTATGCCTTTGTTGGAGAGA

Gene

MIP-1α

MIP-1β

TNFα

iNOS

IL-1β

IκBα

FasL

GFAP

RANTES

CCR5

Reagent Sequences

F; AGCTGACACCCCGACTGC

R; GTCAACGATGAATTGGCGTG

P; TGCTGCTTCTCCTACAGCCGGAAGAT

F; AGCTCTGCGTGTCTGCCC T

R; GCTGAGAACCCTAGAGCACA

P; TCTCCT CTTGCTCGTGGCTGCCTT

F; TCCAGGCGGTGCCTATGT

R; GAGCGTGGTGGCCCC

P; TCAGCCTCTTCTCATTCCTGCTTGTGG

F; TGATGTCCGAAGCAAACATCA

R; TGTGGCTCCCATGTTGCAT

P; TTCAGATCCCGAAACGCTTCACTTCC

F; TTGGGCCTCAAAGGAAAGAAT

R; TCTCCAGCTGCAGGGTGG

P; TATACCTGTCCTGTGTAATGAAAGACGGCA CA

F; CGGAGGACGGAGGACTCGTT

R; ACTTCCATGGTCAGCGGCT

P; TGCACTTGGCAATCATCCACGAAGA

F; TACCACCGCCATCACAACC

R; TTTGTGTTGTGGTCCTTCTTCTTTAG

P; CTCCCACTGCCGCCACTGACC

F; GGAGCTCAATGACCGCTTTG

R; AGCGCCTTGTTTTGCTGCTC

P; CAGCTACATCGAGAAGGTTCG

F; TCTTGCAGTCGTGTTTGTCAC

R; TCTTGAACCCACTTCTTCTCT

P; AGGAACCGCCAAGTGTGTGC

F; GGAATGACACACTGCTGCCTAA

R; GAACACTGAGAGATAACTCCGGAAC

P; CCCTGTCATCTATGCCTTTGTTGGAGAGA


Sexual behaviors	Number (%)

Diagnosed with an STI in the past 6 months	16 (10.8)

Sought treatment for most recent STI symptom (n = 16)	2 (11.1)

Facility where the most recent STI was treated

 Public health center/hospital (n = 2)	1 (50.0)

 Non-governmental clinic/hospital (n = 2)	1 (50.0)

Had sexual intercourse in the past 3 months	59 (41.3)

Used condom in last sexual intercourse (n = 59)	21 (35.6)

Had sexual intercourse when intoxicated (n = 59)	22 (37.3)

Sexual behaviors	Number (%)

Diagnosed with an STI in the past 6 months	16 (10.8)

Sought treatment for most recent STI symptom (n = 16)	2 (11.1)

Facility where the most recent STI was treated

Public health center/hospital (n = 2)	1 (50.0)

Non-governmental clinic/hospital (n = 2)	1 (50.0)

Had sexual intercourse in the past 3 months	59 (41.3)

Used condom i	21 (35

n last sexual intercourse (n = 59)	.6)

Had sexual intercourse when intoxicated (n = 59)	22 (37.3)


Variable	Preview	No-Preview

	IB	No-IB	IB	No-IB


Size Factor	Iterations

Initial	--

1.15	17

1.25	21

1.35	20


Characteristics	Number (%)

Age range (year)	6–88

Mean age (year) (SD)	42.5 ± 17.53

Length of stay (day) range	0–15

Mean length of stay (day) (SD)	8.3 ± 5.3

Length of stay (day)

 ≤1 week	67 (57.7)

 More than one week	21 (18.1)

Sex

 Male	63 (54.4)

 Female	53 (45.6)

Hospitalization

 Yes	87 (75)

 No	29 (25)

Nosocomial infection

 Yes	22 (18.9)

 No	94 (81.1)

MRSA	49 (42.2)

MSSA	67 (57.7)

PVL gene positive	25 (18.3)

MRSA carry PVL gene	14 (28.5)

MSSA carry PVL gene	11 (16.4)


Parameter	Unit	Soil sample

WD1	WD2	WD3	ZR1	ZR2	ZR3

Particle size		SL	SL	SL	SL	SL	SL

pH		8.4	8.3	8.4	8.3	8.6	8.2

EC	dS m−1	2.1	3.2	2.2	3.7	3.0	2.2

CEC	cmol kg−1	19.4	20.7	21.1	22.3	17.2	20.3


HIV Knowledge and Prevention Practices	Men	Women	Test for difference by sexc

n = 755	n = 1369

Yes	No	Don’t know/not sure	Yes	No	Don’t know/not sure

Circumcision	21 (2.9)	685 (92.8)	32 (4.3)	5 (0.4)	1073 (78.8)	283 (20.8)	<0.001

Others	123 (18.5)	451 (67.9)	90 (13.6)	180 (14.3)	828 (66.8)	231 (18.6)	0.02


Doctors	Organisations/ Designated body	GMC

Licensed doctors who are not trainees must:- Have a connection to one organisation (known as a designated body).- Take part in regular appraisal- Collect supporting information for appraisal: 6 types • CPD (annually) • significant events (annually) • review of complaints and complements (as occur) • quality improvement activity • feedback from colleagues • feedback from patients- Reflect on supporting informationAll trainees must:- Have a connection to either a Local Education Training Board or Deanery- Supporting information and discussion of progress and learning needs as generated for curriculum and training programme.	Organisations are required by the GMC to provide:- a RO new role, responsible for the revalidation recommendation)- an up to date appraisal system and ensure every licensed doctor has a regular appraisal- a sufficient number of trained appraisers- clinical governance systems that can provide supporting information- policies and systems for identifying and responding to concerns about doctors- link with other organisations where doctors work, so information about their practice can be sharedRO makes one of three possible revalidation recommendation to the GMC:- Revalidation- Deferral (request for GMC to provide more time for revalidation decision). Does not affect licence to practise.- Non-engagement (can lose licence)	As the regulator the GMC is responsible for:- setting guidelines- Making the final revalidation decision based on RO’s recommendation (to revalidate; how much time to provide for deferral and whether to refer to a Fitness to Practise Panel)- Provide an Employer Liaison Service to help responsible officers with revalidation and the management of concerns about doctors

Doctors

Licensed doctors who are not trainees must:- Have a connection to one organisation (known as a designated body).- Take part in regular appraisal- Collect supporting information for appraisal: 6 types • CPD (annually) • significant events (annually) • review of complaints and complements (as occur) • quality improvement activity • feedback from colleagues • feedback from patients- Reflect on supporting informationAll trainees must:- Have a connection to either a Local Education Training Board or Deanery- Supporting information and discussion of progress and learning needs as generated for curriculum and training programme.

Organisations/ Designated body	GMC

Organisations are required by the GMC to provide:- a RO new role, responsible for the revalidation recommendation)- an up to date appraisal system and ensure every licensed doctor has a regular appraisal- a sufficient number of trained appraisers- clinical governance systems that can provide supporting information- policies and systems for identifying and responding to concerns about doctors- link with other organisations where doctors work, so information about their practice can be sharedRO makes one of three possible revalidation recommendation to the GMC:- Revalidation- Deferral (request for GMC to provide more time for revalidation decision). Does not affect licence to practise.- Non-engagement (can lose licence)	As the regulator the GMC is responsible for:- setting guidelines- Making the final revalidation decision based on RO’s recommendation (to revalidate; how much time to provide for deferral and whether to refer to a Fitness to Practise Panel)- Provide an Employer Liaison Service to help responsible officers with revalidation and the management of concerns about doctors


 	Small-for-gestational age group (n = 10)	Appropriate-for-gestational age group (n = 7)

Age at delivery (years)	27.3 ± 5.2	26.4 ± 6.5

Gestational age at delivery (weeks)	38.4 ± 1.0	39.7 ± 0.7

Birth weight (grams)	2159 ± 506	3156 ± 301*

TGF-β1 levels at 34 weeks (ng/mL)	32.5 ± 3.2	39.2 ± 9.8*

TGF-β1 levels at 38 weeks (ng/mL)	36.04 ± 4.3	36.7 ± 7.0


Output variable	Predictive variables	R2	B(Coef)	p	95%CI	HL*

Cardiovascular risk (PDAY)	Sex	0.271	0.090	< 0.01	0.044-0.183	0,939

Waist circumference	0.043	< 0.01	0.014-0.136

Output variable	Predictive variables	R2	B(Coef)	p	95%CI	HL*

Cardiovascular risk	Se		0	< 0.01	0	0,939


Score cutoff	Sensitivity

≧1	0.96

≧2	0.96

≧3	0.75

≧4	0.63

5	0.21


1-year patient survival	149 (99.3%)	25 (96.2%)	NS


Variables

No. of person-years

No. of incidence CVD

Incidence rate

(per 10,000 person-years)

Unadjusted HRs

Adjusted HRs

Model 1†

Model 2‡


	Skin Prick	sIgE	APT	History

	A	B	A	B	A	B	A	B

D. pteronyssinus 	59	56	56	56	34	39	52	34

Cat dander	54	44	49	46	12	10	23	30

Grass pollen	65	57	75	59	18	15	33	31

Birch pollen	65	49	65	53	11	17	13	20

	Skin Prick	sIgE	APT	History

	A	B	A	B	A	B	A	B

D. pteronyssinus	59	56	56	56	34	39	52	34

Ca	54	4		4	1		2	30


	ZA group (n = 27)	Control group (n = 27)

Age (years), mean (SD)	60.1 (11.7)	59.4 (13.3)

Sex, female:male	15:12	14:13

BMI (kg/m2), mean (SD)	26 (4)	25 (5)

Operation time (minutes), mean (SD)a	118 (27)	103 (17)

Blood loss (mL), mean (SD)	502 (312)	387 (162)

Diagnosis (OA/AVN)	16/11	17/10

	ZA group (n = 27)	Control group (n = 27)

Sex, female:male	15:12	14:13

BMI (kg/m2), mean (SD)	26 (4)	25 (5)

Operation time (minutes), mean (SD)a	118 (27)	103 (17)

Blood loss (mL), mean (SD)	502 (312)	387 (162)

Diagnosis (OA/AVN)	16/11	17/10


Genus	Individuals	Assemblages	Mean vector (μ)	Length of mean vector (r)	Concentration	Circular variance	Circular standard deviation	Rayleigh's Z (P)	Rao's spacing test (P)

Astroblepidae

Astroblepus*	6	3	52°	0.74	1.27	0.26	45°	0.031	< 0.05

Loricariidae

Hypoptopomatinae

Hypoptopoma	7	2	274°	0.22	0.00	0.78	99°	0.722	0.90 > P > 0.50

Hypostominae

Ancistrini

Ancistrus*	44	9	192°	0.45	0.99	0.56	73°	0.000	< 0.01

Baryancistrus†	23	4	14°	0.32	0.67	0.68	87°	0.098	< 0.01

Chaetostoma*	44	5	179°	0.68	1.88	0.32	51°	0.000	< 0.01

Dekeyseria	2	1	271°	1.00	20.46	0.00	4°	0.139	–

Etsaputu*	12	2	120°	0.59	1.36	0.41	59°	0.012	< 0.01

Hemiancistrus*	51	5	60°	0.46	1.03	0.54	72°	0.000	< 0.01

Hopliancistrus	5	1	86°	0.31	0.02	0.69	88°	0.650	0.50 > P > 0.10


	Sodium ibuprofen(geometric means)	Ibuprofen/ poloxamer(geometric means)	Standard ibuprofen(geometric means)	Ratio (%)sodium ibuprofen/ standard ibuprofen	90% confidence interval	Ratio (%)ibuprofen/ poloxamer/ standard ibuprofen	90% confidence interval

AUC 0-0.67 (μg/h/mL)	12.08	5.39	3.52	343.55	227.18-519.53	153.34	101.40-231.89

AUC 0-0.83 (μg/h/mL)	18.03	9.24	6.36	283.49	195.09-411.95	145.21	99.93-211.00

AUC 0-1.00 (μg/h/mL)	23.71	13.65	9.54	248.48	176.57-349.68	143.08	101.67-201.35


Mouse	Number	Rate	Theoretical rate	Theoretical value	χ2 test

Total	657	—	—	—	—

WT	153	1	1	164.25

Heterozygous	330	2.06	2	328.5

KO	174	0.98	1	164.25	0.50759

Mouse	Number	Rate	Theoretical rate

Total	657	—	—

WT	153	1	1

Heterozygous	330	2.06	2

KO	174	0.98	1


Density Measure	Confirmed Spn Casesa	RSV+ Casesb	Controls Targeted for CRP Testingc	Confirmed Non- Spn Bacterial Casesd

NP/OP PCR Spn density	(n = 36)	(n = 858)	(n = 597)	(n = 79)

NP/OP PCR density > 106.9 copies/mLe alone	21 (58.3)	109 (12.7)	73 (12.2)	20 (25.3)

+ CRP ≥40 mg/L	17 (47.2)	33 (3.9)	3 (0.5)	17 (21.5)

+ CRP ≥100 mg/L	15 (41.7)	8 (0.9)	0 (0.0)	14 (17.7)

Whole-blood PCR Spn density	(n = 35)	(n = 847)	(n = 597)	(n = 78)


	Number of patients with positive test result(n = 30)

Spices	27

Seeds and nuts	24

Seafood	24

Starch	22

Food additives	21

Vegetables	21

Cheese	20

Fruits	20

Sugar products	20

Other additives	14

Eggs	14

Milk and milk products	14

Infusions	13

Salads	10

Mushrooms	9

Yeast	5

Meat	5

	Number of patients with positive test result(n = 30)

Spices	27

Seeds and nuts	24

Seafood	24

Starch	22

Food additives	21

Vegetables	21

Cheese	20

Fruits	20

Sugar products	20

Other additives	14

Eggs	14

Milk and milk products	14

	1

Infusions	3

Salads	10

Mushrooms	9

Yeast	5

Meat	5


	n = 88

Patient age (years)Mean ± SD	36 ± 9.3

Sex (female/male)n (%)	60/28 (68.19/31.81 %)

BMI (kg/m2)Mean ± SD	48.65 ± 7.71


	Non-interacting	Interacting

unconstrained	Z-score = 8.17, AUC = 93.48%	Z-score = 7.09, AUC = 91.06%

constrained	Z-score = 4.32, AUC = 87.01%	Z-score = 6.94, AUC = 90.07%

	eracting	ing

unconstrained	Z-score = 8.17, AUC = 93.48%	Z-score = 7.09, AUC = 91.06%

constrained	Z-score = 4.32, AUC = 87.01%	Z-score = 6.94, AUC = 90.07%


	Endocan (pg/ml)	Osteoprotegerin (pmol/l)

Baseline	146 ± 110	4,4 ± 2,4

2 months	168 ± 133	4,5 ± 2,7

4 months	168 ± 134	4,6 ± 2,3

6 months	179 ± 224	4,4 ± 2,0

8 months	196 ± 238	4,3 ± 2,1

Paired sample t-test	p-value = 0,036	p-value = 0,668

Friedman test	Chi-Square: 12,696Asymp. Significance: 0,013	Chi-Square: 8,309Asymp. Significance: 0,081

	Endocan (pg/ml)	Osteoprotegerin (pmol/l)

8 months	196 ± 238	4,3 ± 2,1

Paired sample t-test	p-value = 0,036	p-value = 0,668

Friedman test	Chi-Square: 12,696Asymp. Significance: 0,013	Chi-Square: 8,309Asymp. Significance: 0,081


International source	Range of time requirement in minutes	Average time requirement in minutes

ECDC Round Table Report	< 15–60	40

ProMED-mail	< 15–45	35

WHO Event Information Site (EIS)	< 15–30	25

EPIS for Food- and Waterborne Diseases and Zoonoses (EPIS-FWD)	< 15–30	15

WHO Disease Outbreak News (DON)	< 15–30	20

European Early Warning and Response System (EWRS)	< 15–40	30

Eurosurveillance	< 15–30	25

Emerging Infections (EI) Summary	< 15–45	20

Morbidity and Mortality Weekly Report (MMWR)	< 15	10

WHO Weekly Epidemiological Records (WER)	< 15	10

TOTAL	150–330	230

International source	Range of time requirement in minutes	Average time requirement in minutes

WHO Weekly Epidemiological Records (WER)	< 15	10

TOTAL	150–330	230


Agent	Specific mechanism	Highest level of studies	Result

Tauroursodeoxycholic acid	Chemical chaperone	Randomized controlled trials	Improved insulin sensitivity in muscle and liver in obese individuals [86]

Phenylbutyrate	Chemical chaperone	Randomized controlled trials	Improved insulin sensitivity and beta-cell function in lipid-infused individuals [87]

Azoramide	ATF6 activators	Rodents	Improves insulin sensitivity and beta-cell function in obese mice [89]

Valproate	Increasing GRPP78	Rodents	Ameliorates atherosclerosis and hepatic steatosis in Apoe−/−mice [90]

L-Carnitine or carnitine-orotate	Fatty acid transfer for beta-oxidation	Randomized controlled trials	Twelve of 17 studies showing improved insulin sensitivity or glycemic control in type 2 diabetic patients or alleviation of hepatic steatosis [98, 99]

Co-enzyme Q10	Electron carrier from complex I and II to complex III	Randomized controlled trials	No net effect on glycemic control in type 2 diabetic patients [100]

α-lipoic acid	Antioxidant	Randomized controlled trials; rodent	Weight-reducing, glucose-lowering, and insulin-sensitizing effect; prevention of hepatic steatosis [101–110]

Vitamin E	Antioxidant	Randomized controlled trials	Inconsistent results on glycemic control [111–115]; reduced hepatic steatosis [122]

N-acetylcysteine	Antioxidant	Rodents	Prevents diet-induced obesity [116–118]

Peptide SS31	Mitochondria-targeted antioxidant peptide	Rodent	Improved glucose tolerance in diet-induced obese mice [38]

Resveratrol	SIRT1 agonist	Randomized controlled trials	Improved insulin sensitivity and glycemic control in diabetic patients; no effect in nondiabetic patients [120];

GSK5182	Estrogen-related receptor gamma inverse agonist	Rodents	Reduces hyperglycemia due to inhibition of hepatic gluconeogenesis [121]

Trehalose, imanitib	Enhance autophagy	Rodents	Improved glucose tolerance and insulin sensitivity in obese mice [84]

Dh404	Nrf2 activator	Rodents	Increased viability of islet by enhancing autophagy [123]

Agent	Specific mechanism

Tauroursodeoxycholic acid	Chemical chaperone

Phenylbutyrate	Chemical chaperone

Azoramide	ATF6 activators

Valproate	Increasing GRPP78

L-Carnitine or carnitine-orotate	Fatty acid transfer for beta-oxidation

Co-enzyme Q10	Electron carrier from complex I and II to complex III

α-lipoic acid	Antioxidant

Vitamin E	Antioxidant

N-acetylcysteine	Antioxidant

Peptide SS31	Mitochondria-targeted antioxidant peptide

Resveratrol	SIRT1 agonist

GSK5182	Estrogen-related receptor gamma inverse agonist

Trehalose, imanitib	Enhance autophagy

Dh404	Nrf2 activator

Highest level of studies	Result

Randomized controlled trials	Improved insulin sensitivity in muscle and liver in obese individuals [86]

Randomized controlled trials	Improved insulin sensitivity and beta-cell function in lipid-infused individuals [87]

Rodents	Improves insulin sensitivity and beta-cell function in obese mice [89]

Rodents	Ameliorates atherosclerosis and hepatic steatosis in Apoe−/−mice [90]

Randomized controlled trials	Twelve of 17 studies showing improved insulin sensitivity or glycemic control in type 2 diabetic patients or alleviation of hepatic steatosis [98, 99]

Randomized controlled trials	No net effect on glycemic control in type 2 diabetic patients [100]

Randomized controlled trials; rodent	Weight-reducing, glucose-lowering, and insulin-sensitizing effect; prevention of hepatic steatosis [101–110]

Randomized controlled trials	Inconsistent results on glycemic control [111–115]; reduced hepatic steatosis [122]

Rodents	Prevents diet-induced obesity [116–118]

Rodent	Improved glucose tolerance in diet-induced obese mice [38]

Randomized controlled trials	Improved insulin sensitivity and glycemic control in diabetic patients; no effect in nondiabetic patients [120];

Rodents	Reduces hyperglycemia due to inhibition of hepatic gluconeogenesis [121]

Rodents	Improved glucose tolerance and insulin sensitivity in obese mice [84]

Rodents	Increased viability of islet by enhancing autophagy [123]


Factor	Parameter Estimate (95% CI)	P

Mean arterial blood pressure

 Smoker	3.49 (−2.67, 9.64)	.257

 Male sex	−38.45 (−91.78 to 14.88)	.151

 Age	0.25 (−.14 to .64)	.202

 Body mass index	0.19 (−.61 to .99)	.625

 Antihypertensive	1.44 (5.19–8.06)	.662

 CD4+ iTreg count,a per 10-fold increase	20.72 (7.03–34.41)	.004

 Sex-associated CD4+ iTreg frequencyb	−18.40 (−41.80 to 4.99)	.119

Diastolic blood pressure

 Smoker	3.09 (−3.54 to 9.72)	.349

Male sex	−62.14 (−119.59 to −4.70)	.035

 Age	−0.04 (−.45 to .38)	.858

 Body mass index	0.44 (−.42 to 1.30)	.301

 Antihypertensive	1.86 (−5.28 to 8.99)	.600

 CD4+ iTreg count, per 10-fold increase	21.50 (6.75–36.25)	.006

 Sex-associated CD4+ iTreg frequencya,b	−28.07 (−53.27 to −2.87)	.030


Parameter	Univariate analysis	Multivariate analysis

HR(95% CI)	P-value	HR (95% CI)	P-value

Gender

Female	1(Referent)

Male	3.272 (1.781-6.01)	0.091

Histology

WHO Type 2	1(Referent)

WHO Type 3	0.813(0.539-1.227)	0.324

Age at diagnosis (years)

<50	1(Referent)

≥50	1.154(0.751-1.773)	0.513

Tumor classification

T1+2	1(Referent)

T3+4	2.876(1.814-4.558)	<0.001	1.847 (1.106-3.084)	0.019

Lymph node classification

N0+1	1(Referent)

N2+3	2.550(1.644-3.953)	<0.001	1.827 (1.126-2.966)	0.015

TNM stage(AJCC)


Cat no.	Category	No. of questions

Questionnaire 1 (QS1)	24

n/a	Have you ever heard of masesea?	1

1	Acquisition & transmission of T. solium infections	3

2	Acquisition of NCC	2

3	TS in general	3

4	NCC in general	3

5	PCC diagnosis	4

6	PCC treatment	2

7	Relationship between PCC/TS/NCC	3

8	Prevention of PCC/TS/NCC	3

Questionnaire 2 (QS2)	15

1	General knowledge	5

2	Transmission	5

3	Prevention	5


CD274/PD-L1 FISH	Cases	PD-L1 IHC

	n = 80	Score3+	Score2+	Score1+	Score0

High Level Amplification	12 (15%)	7/12	1/12	2/12	2/12

Low Level Amplification	3 (4%)	1/3	0/3	0/3	2/3

Polysomy	16 (20%)	3/16	3/16	3/16	7/16


Statement	Agree (%)	Disagree (%)	? (%)

1. A man doesn't reach a orgasm during sexual intercourse. Still, the woman can become pregnant.	50	34	16

2. It is unhealthy to use the oral contraceptive pill for a period longer than 10 years.	44	14	42

3. If a woman uses the oral contraceptive pill, she can become infertile.	22	60	18

4. If a woman uses the oral contraceptive pill, her desire for sex becomes less.	7	73	20

5. The oral contraceptive pill is the most reliable contraceptive method.	49	43	8

6. The injectable contraceptive contains hormones, just as the oral contraceptive pill.	63	6	31

7. An intrauterine device can reside in the uterus without problems for 5 years.	42	20	38

8. A condom is not reliable because it ruptures rapidly.	39	53	8


	Without vaccination	With vaccinationa	Difference

Casesb	59,495	25,281	34,214

 Treated at home	47,622	22,389	25,232

 GP visits	11,453	2,786	8,667

 Hospitalised (community acquired)	2,817	353	2,464

 Hospitalised (nosocomial)	421	106	315

 Deaths	0.65	0.16	0.48

Total QALYs lostc	173	64	109

Total direct costsa (x1000)c	€ 7,470	€ 1,185	€ 6,282

Total indirect costs (x1000) c	€ 2,193	€ 888	€ 1,305

Casesb

Treated at home

GP visits

Hospitalised (community acquired)

Hospitalised (nosocomial)

Deaths

Total QALYs lostc

Total direct costsa (x1000)c

Total indirect costs (x1000) c


Data set	Variance component (%)

	Among groups	Among populations within group	Within populations

All six cattle breeds	7.80	0.70	91.45

Indigenous and local developed breeds	7.80	1.40	90.80


Individual/Demographic	Total Leisure Time Physical Activity (LTPA)

(ALL) n = 428	T1 n = 143	T2 n = 142	T3 n = 143	p Trend

Sex					<0.001

Men	182 (42.5%)	49 (34.3%)	51 (35.9%)	82 (57.3%)

Wom	246		91 (	61 (


	Bayes Factor 10	Bayes Factor 30

	Blood	Brush	Blood

Mean # CNVS per subject	314.0	385.7	151.5

Size of CNVs (kb)

Mean	15.9	16.2	19.9

25th percentile	1.0	1.1	1.0

Median	2.1	2.1	1.9

75th percentile	6.0	5.8	4.4

Size of CNVs (probes)

Mean	15.9	16.6	17.2

25th percentile	12.0	12.0	13.0

Median	16.0	16.0	17.0

75th percentile	18.0	18.0	18.0


	Practices in first cohort	Practices in second cohort

Practice characteristic	2006-2008	2009-2011	2009-2011

	N	%	N	%	N	%

Practice type

Single handed	17	25%	18	26%	19	27%

Health center	10	14%	11	16%	8	12%

Other	42	61%	40	58%	42	61%

Practice location1

Urban	23	33%	23	33%	25	36%

Semi-urban	34	49%	34	49%	33	48%

Rural	12	18%	12	18%	11	16%

Average number of patients per practice	4629		4808		4830


Males

Prenatal stress

6.2 ± 1.6

43.2 ± 2.7

66.2 ± 2.8


Storage time	Test organism exposed to (name of the test)	Staphylococcus aureus	Staphylococcus epidermidis	Micrococcus luteus	Corynebacterium jeikeium	Candida albicans

< 1 min	neutralizer in saline peptone water (neutralizer toxicity test)	1.86 ± 0.05	1.81 ± 0.03	1.77 ± 0.01	1.82 ± 0.02	2.05 ± 0.01

	antiseptic solution (material control test)	0*	0*	0*	0*	0*

	saline peptone water (organism viability test)	1.90 ± 0.05	1.84 ± 0.07	1.74 ± 0.03	1.79 ± 0.02	2.02 ± 0.03

3 h	neutralizer in saline peptone water (neutralizer toxicity test)	1.83 ± 0.02	1.81 ± 0.02	1.72 ± 0.03	1.89 ± 0.08	2.05 ± 0.06

	antiseptic solution (material control test)	0*	0*	0*	0*	0*

	saline peptone water (organism viability test)	1.88 ± 0.06	1.81 ± 0.02	1.73 ± 0.05	1.77 ± 0.08	2.03 ± 0.02

Test organism exposed to (name of the test)	Staphylococcus aureus	Staphylococcus epidermidis	Micrococcus luteus	Corynebacterium jeikeium	Candida albicans

antiseptic solution (material control test)	0*	0*	0*	0*	0*

saline peptone water (organism viability test)	1.88 ± 0.06	1.81 ± 0.02	1.73 ± 0.05	1.77 ± 0.08	2.03 ± 0.02


Samples	Number	Gender	Age	Mean age

Controls (n = 15)	7	Male	32–77	51.1 ± 15.3

8	Female	46–61	52.6 ± 4.9

Symptomatic HD (n = 16)	8	Male	48–65	60.6 ± 5.6

8	Female	46–67	55.2 ± 7.3

Samples	Number

Controls (n = 15)	7

8

Symptomatic HD (n = 16)	8

8


Haplotype	case(frequency)	control(frequency)	P-value	OR(95% CI)

	3	85		1.039 [0.826~ 1.306


Age group	Number of patients with condylar changes

20–40 (Group A)	16 (64%)

41–60 (Group B)	22 (88%)

61 and above (Group C)	23 (92%)


Type of Intervention	Overall mean blood : sweat ratio

BDE 28	BDE 47	BDE 99	BDE 100	BDE 153

Exercise (n = 3)	137.2	25.5	4.8	16.9	26.9

Infrared sauna (n = 8)	17.9	32.1	3.25	94.6	71.8

Steam sauna (n = 6)	69.5	26.3	5.6	2.4	121.2


Key barriers	Key facilitators

Capabilities: Stress associated with being an asylum seeker	Stress drove activity

Decision process: Living in limbo	Feeling settled and secure

Resources and environment Lack of money for food and equipment Lack of knowledge of facilities in local area The weather Time Lack of childcare

Social

 Exercising With friends/ family Alone in the UK Cultural influences	Exercising With friends/ family

Knowledge and skills

 The phrase ‘physical activity’ and recommended levels	Levels of exercise and physical activity back home

	Understanding consequences Impact on physical health Weight gain Impact on mental health

Key barriers	Key facilitators

Social

Exercising With friends/ family Alone in the UK Cultural influences	Exercising With friends/ family

Knowledge and skills

The phrase ‘physical activity’ and recommended levels	Levels of exercise and physical activity back home

	Understanding consequences Impact on physical health Weight gain Impact on mental health


Disease	miRNA	Expression level	Contributors

Breast cancer	miR-29a	Up-regulation	Wu et al., J Biomed Biotechnol. (2010) [76]

 	miR-21	 	Asaga et al., Clin Chem. (2011) [77]

Lung cancer	miR-21,1254,574-5p	Up-regulation	Wei et al., Chin J Cancer. (2011) [79]

 	 	 	Foss et al., J Thorac Oncol. (2011) [78]

Hepatocellular carcinoma	miR-16,miR-199a	Down-regulation	Qu et al., J Clin Gastroenterol. (2011) [80]

 	miR-21,miR-122,miR-223	Up-regulation	Xu et al., Mol Carcinog. (2010) [81]

Malignant melanoma	miR-221	Up-regulation	Kanemaru et al., J Dermatol Sci. (2011) [82]

Gastric cancer	miR-1,20a,27a,34,423-5p	Up-regulation	Liu et al., Eur J Cancer. (2011) [83]

Disease	miRNA	Expression level	Contributors

	-21		Asaga et al., Clin Chem. (2011) [77]

Lung cancer	miR-21,1254,574-5p	Up-regulation	Wei et al., Chin J Cancer. (2011) [79]

			Foss et al., J Thorac Oncol. (2011) [78]

Hepatocellular carcinoma	miR-16,miR-199a	Down-regulation	Qu et al., J Clin Gastroenterol. (2011) [80]

	miR-21,miR-122,miR-223	Up-regulation	Xu et al., Mol Carcinog. (2010) [81]

Malignant melanoma	miR-221	Up-regulation	Kanemaru et al., J Dermatol Sci. (2011) [82]

Gastric cancer	miR-1,20a,27a,34,423-5p	Up-regulation	Liu et al., Eur J Cancer. (2011) [83]


		Southern zone	Middle zone	Northern zone

Indication	Medicine name	Before	After	Before	After	Before	After

Malaria	ACTs	53.80	7.70	33.30	0	40.00	0

Asthma	Salbutamol	25.00	7.70	26.70	6.20	0	20.00

Diabetes	Gilbendamide	38.50	30.80	20.00	18.80	60.00	60.00

Cardiovascular disease	Atenolol	58.30	23.10	20.00	25.00	40.00	40.00

Depression	Amitriptyline	58.30	38.50	33.30	50.00	60.00	60.00

Infectious disease	Ciprofloxacin	8.30	0	13.30	6.20	20.00	0

Infectious disease	Co-trimoxazole	25.00	7.70	6.00	6.20	0	0

Infectious disease	Amoxiillin	15.40	7.70	13.30	6.20	20.00	0

Central nervous system disease	Diazepam	15.40	7.70	13.30	6.20	20.00	50.00

Ulcer	Omeprazole	30.80	15.40	26.50	18.80	25.00	50.00


Paper	# of patients	Types of mutations

Bartsch et al 1997 [7]	1	Translocation

Matsumoto et al 1997 [6]	1	Deletion

Møller et al 2008 [8]	2	2 translocations

Fujita et al 2010 [9]	1	Deletion

Oegema et al 2010 [10]	2	2 deletions

Yamamoto et al 2011 [11]	3	3 deletions

van Bon et al 2011 [12]	1	Deletion

Valetto et al 2012 [13]	1	Deletion

Courcet et al 2012 [14]	2	1 deletion, 1 frameshift

O’Roak et al 2012 [15]	3	2 frameshifts, 1 splice site

Okamoto et al 2015 [27]	1	Nonsense

Redin et al 2014 [16]	2	1 nonsense, 1 frameshift

Iglesias et al 2014 [17]	1	Nonsense

Ruaud et al 2015 [19]	2	1 nonsense, 1 missense

van Bon et al 2015 [18]	5	2 nonsense, 3 splice site

Bronicki et al 2015 [20]	10	3 nonsense, 2 missense, 4 frameshift, 1 deletion

Ji et al 2015 [21]	14	3 nonsense, 3 missense, 3 frameshift, 5 deletions


Name	Origin	Sex	C14 Date (calibrated)	Endogenous (%)	Unique (%)	MT and Y haplogroup	Mean autosomal coverage

L	Linton	Female	360–50 BCE	72	54	H1e	1.4

HI1	Hinxton	Male	160 BCE–26 CE	16	63	K1a1b1b, R1b1a2a1a2c	1.3

HI2	Hinxton	Male	170 BCE–80 CE	83	65	H1ag1, R1b1a2a1a2c1	11.8

O1	Oakington	Female	420–570 CE	81	50	U5a2a1	3.8

O2	Oakington	Female	385–535 CE	92	68	H1g1	2.7

O3	Oakington	Female	395–540 CE	95	64	T2a1a	8.2

O4	Oakington	Female	400–545 CE	67	77	H1at1	6.3

HS1	Hinxton	Female	666–770 CE	36	91	H2a2b1	4.4

HS2	Hinxton	Female	631–776 CE	42	74	K1a4a1a2b	3.8

HS3	Hinxton	Female	690–881 CE	16	71	H2a2a1	0.9

Name	Origin	Sex	C14 Date (calibrated)	Endogenous (%)	Unique (%)	MT and Y haplogroup	Mean autosomal coverage

HS3	Hinxton	Female	690–881 CE	16	71	H2a2a1	0.9


Evaluation criteria	Medium range contacts	Long range contacts

Top L/5	.34 (.18)	.30 (.05)

Top L/5, δ = 1	.55 (.27)	.48 (.07)

Top L/5, δ = 2	.64 (.29)	.56 (.08)

Evaluation criteria	Medium range contacts	Long range contacts

Top L/5	.34 (.18)	.30 (.05)

Top L	.	.


 	 	Mean fold change	Upper limit C.I	Lower limit C.I

AHPC	Overexpressed in virulent strains compared to the avirulent ATCC 33658 T

Transcription Ratio of AHPC in the virulent strains compared to ATCC 33658 T:	5.80E + 01	1.38E + 02	2.17E + 01

ATP-F	Overexpressed under iron-deprived conditions

 	Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:	2.50E + 01	4.73E + 01	1.32E + 01

Enolase	Overexpressed under iron-deprived conditions

 	Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:	6.10E + 02	2.23E + 03	1.68E + 02

H-NS	Under-expressed under iron-deprived conditions

 	Transcription Ratio of the iron-rich cultures compared to the iron-poor ones:	1.89E + 03	3.29E + 03	1.09E + 03

VapA	Overexpressed under iron-deprived conditions

 	Transcription Ratio of the iron-poor cultures compared to the iron-rich ones:	3.65E + 01	5.14E + 01	2.64E + 01


Years of formal education	Frequency (% out of n=43)	Frequency of Cognitive Dysfunction (%)	Frequency of normal Cognition (%)	Chi-square (x2) test	p-value

More than 12 years	16 (37.2)	8 (50.0)	8 (50.0)	2.563	0.11 (>0.05)

Less than 12 years	27 (62.8)	20 (74.1)	7 (25.9)

Years of formal education	Frequency (% out of n=43)	Frequency of Cognitive Dysfunction (%)	Frequency of normal Cognition (%)	Chi-square (x2) test	p-value

Less than 12 years	27 (62.8)	20 (74.1)	7 (25.9)	2.563	0.11 (>0.05)


Type/site of TB	HIV-TB group

PTB [n(%)]	25 (20)*

EPTB [n(%)]	98 (80)

DTB [n(%)]	39 (32)

Lung + Pleura + mediastinal LN [n(%)]	11 (9)*

Pleura + RP/mesenteric LN [n(%)]	6 (5)

Lung + pleura [n(%)]	4 (3)

Ascites + RP/mesenteric LN + mediastinal LN [n(%)]	4 (3)

Ascites + hepatosplenomegaly + RP/mesenteric LN + mediastinal LN [n(%)]	3 (2)

Lung + pleura + Ascites + RP/mesenteric LN [n(%)]	3 (2)

Ascites + hepatosplenomegaly + mediastinal LN [n(%)]	2 (2)

Lung + pleura + Ascites + hepatosplenomegaly + RP/mesenteric LN [n(%)]	2 (2)

Lung + pleura + Ileocaecal + RP/mesenteric LN [n(%)]	2 (2)

Cervical LN + mediastinal LN + RP/mesenteric LN [n(%)]	2 (2)

Abdomen [n(%)]	23 (19)

Ascites + RP/mesenteric LN [n(%)]	8 (7)

Ascites + hepatosplenomegaly + RP/mesenteric LN [n(%)]	7 (6)

Ascites + hepatosplenomegaly [n(%)]	4 (3)

Ileocaecal + RP/mesenteric LN [n(%)]	4 (3)

Lymph node [n(%)]	16 (13)

Cervical [n(%)]	10 (8)†

Abdominal [n(%)]	4 (3)

RP + mesenteric LN	2 (2)

RP LN	1 (1)

Periportal + mesenteric LN	1 (1)

Mediastinal [n(%)]	2 (2)

Pleural effusion [n(%)]	11 (9)

CNS [n(%)]	6 (5)

Meningitis [n(%)]	3 (2)

Tuberculoma [n(%)]	2 (2)

Meningitis + Tuberculoma [n(%)]	1 (1)

MTB [n(%)]	2 (2)

Pott's spine [n(%)]	1 (1)

Type/site of TB	HIV-TB group

Lymph node [n(%)]	16 (13)

Cervical [n(%)]	10 (8)†

Abdominal [n(%)]	4 (3)

RP + mesenteric LN	2 (2)

RP LN	1 (1)

Periportal + mesenteric LN	1 (1)

Mediastinal [n(%)]	2 (2)

Pleural effusion [n(%)]	11 (9)

CNS [n(%)]	6 (5)

Meningitis [n(%)]	3 (2)

Tuberculoma [n(%)]	2 (2)

Meningitis + Tuberculoma [n(%)]	1 (1)

MTB [n(%)]	2 (2)

Pott's spine [n(%)]	1 (1)


Dataset type	Control dataset	Real sample dataset

Dataset Name	D1	D2	D3	D4	D5	D6

Instrument	LCQ	LTQ	LTQ/FT	LCQ	LTQ	LTQ/FT

Reference or notes	[46]	[55]	unpublished	[44]	[56]	unpublished

Sample	12 purified proteins + 23 peptides	49 purified human proteins	8 purified proteins	Human K562 cell line	Human liver	Human Liver

Data source	the BIATECH Institute (Bothell, WA 98011, USA)	Proteomics Standards Research Group (sPRG) [55]	Beijing proteome Research Center (Beijing 102206, China)	Open Proteomics Database (OPD)[57]	Beijing proteome Research Center (Beijing 102206, China)	Beijing proteome Research Center (Beijing 102206, China)


Group	N (Male/Female)	Maternal Age (Years)	Maternal BMI before Pregnancy	Gestational Age (Weeks)	Birth Weight (g)	Body Length (cm)	Ponderal Index (kg/m3)	Head Circumference (cm)	Placenta Weight (g)

NBW	12 (6/6)	31 ± 3	21.3 ± 2.2	39.1 ± 0.8	3452 ± 96	50.8 ± 1.1	26.2 ± 1.4	34.6 ± 0.8	701.2 ± 106.7

LB	12 (6/	31 ± 	21.1 ± 	3	2623 ± 20	49.2 ± 4	23.	31.9 ± 1.6	492.8


Result/PCR target positivity	Interpretation/meaning	Action

G3PD 567 bp (+)	Valid results for parasite diagnosis	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (+)

G3PD 567 bp (+)	Valid results for parasite diagnosis despite small loss of DNA in extraction	Conclude diagnostic test observation

pUC 316 bp (-)

L. braziliensis 138 bp (+)

G3PD 567 bp (-)	Valid results for parasite diagnosis despite small degradation of sample	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (+)

G3PD 567 bp (-)	Degradation of DNA sample/presence of PCR inhibitors and/or whole DNA loss during extraction	Repeat diagnostic procedure since the blood sample collection

pUC 316 bp (-)

L. braziliensis 138 bp (-)

G3PD 567 bp (-)	Degradation of DNA sample before extraction	Repeat diagnostic procedure since the blood sample collection

pUC 316 bp (+)

L. braziliensis 138 bp (-)

G3PD 567 bp (+)	Significant DNA loss (affecting mainly parasite genome) during extraction process	Repeat the DNA extraction procedure

pUC 316 bp (-)

L. braziliensis 138 bp (-)

G3PD 567 bp (+)	True negative result for Leishmania detection assured by the positivity of quality controls	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (-)

Result/PCR target positivity	Interpretation/meaning	Action

G3PD 567 bp (+)	Valid results for parasite diagnosis despite small loss of DNA in extraction	Conclude diagnostic test observation

pUC 316 bp (-)

L. braziliensis 138 bp (+)

G3PD 567 bp (-)	Valid results for parasite diagnosis despite small degradation of sample	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (+)

G3PD 567 bp (-)	Degradation of DNA sample/presence of PCR inhibitors and/or whole DNA loss during extraction	Repeat diagnostic procedure since the blood sample collection

pUC 316 bp (-)

L. braziliensis 138 bp (-)

G3PD 567 bp (-)	Degradation of DNA sample before extraction	Repeat diagnostic procedure since the blood sample collection

pUC 316 bp (+)

L. braziliensis 138 bp (-)

G3PD 567 bp (+)	Significant DNA loss (affecting mainly parasite genome) during extraction process	Repeat the DNA extraction procedure

pUC 316 bp (-)

L. braziliensis 138 bp (-)

G3PD 567 bp (+)	True negative result for Leishmania detection assured by the positivity of quality controls	Conclude diagnostic test observation

pUC 316 bp (+)

L. braziliensis 138 bp (-)


Microtiter plate [28]	Microtiter plate [29]	RISE [30]

Round 1 (h)	Round 1 (h)	Round 1 (h)

Target incubation	18	Target incubation	2	Target incubation	18

Wash-postcoat	2.25	Wash-postcoat	1.5	Wash-postcoat	4

Phage incubation	1	Phage incubation	1	Cell growth tubes	3

Wash-elution	0.5	Wash-elution	2.25	Infection	3

Infection		Infection		Wash	0.5

- amplification	4.5	- amplification	5	Cell/phage/target incubation	16

Phage recovery	0.5	Phage recovery	18	Phage recovery	0.5

Time	~27 h		~30 h		~45 h

2 additional panning rounds		2 additional panning rounds		3 additional panning rounds

TOTAL TIME	~81 h		~90 h		~180 h

Microtiter plate [28]

Round 1 (h)

Target incubation	18

Wash-postcoat	2.25

Phage incubation	1

Wash-elution	0.5

Infection

- amplification	4.5

Phage recovery	0.5

Time	~27 h

2 additional panning rounds

TOTAL TIME	~81 h

Microtiter plate [29]	RISE [30]

Round 1 (h)	Round 1 (h)

Target incubation	2	Target incubation	18

Wash-postcoat	1.5	Wash-postcoat	4

Phage incubation	1	Cell growth tubes	3

Wash-elution	2.25	Infection	3

Infection		Wash	0.5

- amplification	5	Cell/phage/target incubation	16

Phage recovery	18	Phage recovery	0.5

	~30 h		~45 h

2 additional panning rounds		3 additional panning rounds

	~90 h		~180 h


	Group

Variables	G1: Nordic walking (N=8)	pa	G2: Water aerobics (N=8)	pa	G3: Non-exercising (N=8)	pa	pb

Baseline	Eight weeks	Baseline	Eight weeks	Baseline	Eight weeks

RT right (s)	39.1 ± 10.83	31.0 ± 10.45	0.04*	32.3 ± 16.82	33.6 ± 15.10	0.11	25.3 ± 9.30	24.9 ± 9.03	0.40	0.08


Time Series	Germ layer	TP#	Switching#	Gene#	%	Non-Xover	%	Xover	%

Cerebellar development	Ectoderm	12	48,489	5433	21.6	38,722	79.9	9767	20.1

Human iPS to neuron (wt) 1	Ectoderm	4	45,069	6692	26.5	41,302	91.6	3767	8.4

Trachea epithelia differentiation	Endoderm	19	8389	2458	9.8	6112	72.9	2277	27.1

Adipocyte differentiation	Mesoderm	16	66,087	5996	23.8	57,857	87.5	8230	12.5

Epithelial to mesenchymal	Mesoderm	21	132,661	7004	27.8	109,252	82.4	23,409	17.6

BMM TB activation IL13	Mesoderm	11	825	527	2.1	564	68.4	261	31.6

AoSMC response to IL1b	Mesoderm	10	192	159	0.6	129	67.2	63	32.8

Macrophage response to LPS	Mesoderm	23	32,234	4557	18.1	22,239	69.0	9995	31.0

ES to cardiomyocyte	Mesoderm	13	189	163	0.6	100	52.9	89	47.1

Myoblast to myotube	Mesoderm	9	21,912	4249	16.9	18,735	85.5	3177	14.5

Time Series	Germ layer	TP#	Switching#	Gene#	%	Non-Xover	%	Xover	%

Cerebellar development	Ectoderm	12	48,489	5433	21.6	38,722	79.9	9767	20.1

Human iPS to neuron (wt) 1	Ectoderm	4	45,069	6692	26.5	41,302	91.6	3767	8.4

Trachea epithelia differentiation	Endoderm	19	8389	2458	9.8	6112	72.9	2277	27.1

Adipocyte differentiation	Mesoderm	16	66,087	5996	23.8	57,857	87.5	8230	12.5

Epithelial to mesenchymal	Mesoderm	21	132,661	7004	27.8	109,252	82.4	23,409	17.6

BMM TB activation IL	M	11	8	52	2.1	56		261

Time Series	Germ layer	TP#	Switching#	Gene#	%	Non-Xover	%	Xover	%

13	esoderm		25	7		4	68.4		31.6

AoSMC response to IL1b	Mesoderm	10	192	159	0.6	129	67.2	63	32.8

Macrophage response to LPS	Mesoderm	23	32,234	4557	18.1	22,239	69.0	9995	31.0

ES to cardiomyocyte	Mesoderm	13	189	163	0.6	100	52.9	89	47.1

Myoblast to myotube	Mesoderm	9	21,912	4249	16.9	18,735	85.5	3177	14.5


Variable	Univariate analysis	Multivariate analysis

Hazard ratio	Confidence interval	p-value	Hazard ratio	Confidence interval	p-value

NKp30, C1D1, LFS	0.24	0.099–0.61	0.002	0.14	0.043–0.43	0.001

NKp30, C1D1, OS	0.28	0.088–0.91	0.034	0.17	0.037–0.78	0.022

Variable	Univariate analysis	Multivariate analysis

Hazard ratio	Confidence interval	p-value	Hazard ratio	Confidence interval	p-value

NKp46, C1D21, LFS	0.25	0.10–0.59	0.001	0.28	0.093–0.82	0.020

NKp46, C1D21, OS	0.21	0.067–0.66	0.007	0.22	0.047–1.05	0.058


Number	Data Source	Age/years	Professional background

1	Focus group	53	Bereavement counselor

2	Focus group	39	Communication consultant

3	Focus group	46	Director & Trainer PR Company

4	Focus group	50	Dietician

5	Focus group	47	Fitness trainer

6	Focus group	36	General practitioner

7	Focus group	45	Social worker

8	Assignment	55	Facilitator in development sector

9	Assignment	55	Physiotherapist

10	Assignment	69	Counselor

11	Assignment	39	Communication consultant

12	Assignment	61	Nurse practitioner/Health coach

13	Assignment	55	Executive coach

14	Assignment	44	Clinical psychologist

15	Assignment	36	General practitioner

16	Assignment	54	General practitioner

17	Assignment	42	Social Worker

Number	Data Source	Age/years	Professional background

8	Assignment	55	Facilitator in development sector

9	Assignment	55	Physiotherapist

10	Assignment	69	Counselor

11	Assignment	39	Communication consultant

12	Assignment	61	Nurse practitioner/Health coach

13	Assignment	55	Executive coach

14	Assignment	44	Clinical psychologist

15	Assignment	36	General practitioner

16	Assignment	54	General practitioner

17	Assignment	42	Social Worker


Characteristic	Training set	Testing set	Total

Age

 Median	59	58	59

 Range	38∼85	30∼87	30∼87

Clinical stage

 Stage I	0	0	0

 Stage II	8	13	21

 Stage III	163	158	321

 Stage IV	31	31	62

Vital status

 Living	91	88	179

 Dead	112	116	228

Characteristic	Training set	Testing set	Total

Living	91	88	179

Dead	112	116	228


 	All cases (n)	Fatality (n)	CFR(95%CI) (%)	RSE (%)

Pre-intervention period

(Eclampsia patients)	1233	258	20.9(18.7, 23.2)	5.5

Intervention period

(Eclampsia patients)	996	23	2.3(1.4, 3.2)	20.9


Certified Reference Materials	DON Immunosensor (ppm)	ELISA (ppm)	Vendor (ppm)

Wheat	0.3	0.2	0.71

Corn	0.92	1.1	1.88

Roasted coffee	0.19	0.24	0.77


 	Confidence ratings at end of module (N≥294)	Confidence ratings 3–6 Months after completion (N≥106)

Mean1	%2	Mean1	%2

Respondent’s Confidence in his or her ability to:

(a) diagnose depression	1.23	99.7	1.19	100

(b) screen for addictions	1.74	92.4	1.67	94.5

(c) screen for other mental health conditions	1.83	91.8	1.73	96.3

(d) treat depression	1.43	99.0	1.28	100

(e) treat other mental health disorders	1.99	85.2	1.93	87.2

(f) prescribe medications for mental health conditions	1.67	95.0	1.61	95.5

(g) assess patients’ problems and strengths	1.79	91.0	1.66	92.7

(h) develop systematized care plans for patients where a mental health care plan is not appropriate	2.07	77.5	1.86	84.0

(i) create a mental health care plan fitting Medical Service Plan [provincial program] guidelines	1.87	83.4	1.69	89.8

(j) engage mental health patients in a range of interventions (e.g., cognitive behavioural and interpersonal skills training)	1.97	81.4	1.90	82.6

(k) offer and coach the Antidepressant Skills Workbook	1.95	80.2	1.83	85.0

(l) offer and support the Bounce Back program	1.54	92.1	1.56	91.7

(m) In general, how confident are you in the quality of mental health care you provide to your patients?	1.71	96.3	1.46	99.1

Respondent’s confidence in her or his knowledge/awareness of:

(a) non-pharmacological interventions (cognitive behavioral skills such as activation, relaxation, negative thinking)	1.90	86.8	1.76	91.7

(b) regional mental health resources for mental health patients	2.05	82.8	1.87	88.1


Reaction	Genes	Primer names	Forward primer sequence	Reverse primer sequence	Size (bp)

	hsp60 (groEL_1)	hsp3/hsp4	GACCGCCAGTTAAGATAGCG	TCTCTAGCTACTTCGCAACAAATCC	297

1	CTL0626	CTL06265'F/CTL06265'R	GCACACCATCACTATCAC	GCGCTTGCTTGAGATTTC	226

2	CTL0627	CTL06275'F/CTL06275'R	GTTGGCGAGTCCGATGATG	GACTTCTAATACAGCACCATGTTTG	195

3	CTL0628	CTL06285'F/CTL06285'R	GAAACGGTCTCCTACTAGC	GGTGGGAAGAAATAGTTAAGG	357

Reaction	Genes	Primer names	Forward primer sequence	Reverse primer sequence	Size (bp)

	hsp60 (groEL_	hsp3	GACCGCCAGTTAAGAT	TCTC	297

	1)	/hsp4	AGCG	TAGCTACTTCGCAACAAATCC

1	CTL0626	CTL06265'F/CTL06265'R	GCACACCATCACTATCAC	GCGCTTGCTTGAGATTTC	226

2	CTL0627	CTL06275'F/CTL06275'R	GTTGGCGAGTCCGATGATG	GACTTCTAATACAGCACCATGTTTG	195

3	CTL0628	CTL06285'F/CTL06285'R	GAAACGGTCTCCTACTAGC	GGTGGGAAGAAATAGTTAAGG	357


Impact factors	P-value	Impact factors	P-value

Epidemiologic information		Chemotherapy detail

Age at diagnosis	0.335	PEB/PVB	0.043

Ethnic group	0.856	Bleomycin/pingyangmycin	0.755

Individual history		Weekly/monthly	0.031

Prior lung disease	1.000	Route of administration	0.041

Allergic history	0.603	Cumulative dose	0.000

Disease state		Average course interval	0.256

Stage of disease	0.081	Combined treatment

Histological subtype	0.741	G-CSF	0.331

Side effects of treatment		Antibiotics	0.904

Renal dysfunction	0.001	Blood transfusion	-

Drug allergy	0.332	Erythrocyte	0.116

Granulopenia	0.176	Thrombocyte	0.035

Anemia	0.041	Chalybeate	0.067

Thrombocytopenia	0.000	Post-chemotherapy surgery	0.072

Impact factors	P-value	Impact factors	P-value

Epidemiologic information		Chemotherapy detail

Age at diagnosis	0.335	PEB/PVB	0.043

Ethnic group	0.856	Bleomycin/pingyangmycin	0.755

Individual history		Weekly/monthly	0.031

Prior lung disease	1.000	Route of administration	0.041

Allergic history	0.603	Cumulative dose	0.000

Disease state		Average course interval	0.256

Stage of disease	0.081	Combined treatment

Histological subtype	0.741	G-CSF	0.331

Side effects of treatment		Antibiotics	0.904

Renal dysfunction	0.001	Blood transfusion	-

	0.33	Eryth	0

Drug allergy	2	rocyte	.116

Granulopenia	0.176	Thrombocyte	0.035

Anemia	0.041	Chalybeate	0.067

Thrombocytopenia	0.000	Post-chemotherapy surgery	0.072


>Stage of development	>WT versus AS	>WT versus OE

Immature green	234	333

Mature green	68	112

Red ripe	105	332

Total	407	777


No.	shRNA Targets of RB1

siRNA-RB1-2	GGGUUGUGUCGAAAUUGGATT

siRNA-RB1-4	GGAGUAUGAUUCUAUUAUATT

Negative control siRNA (NC siRNA)	UUCUCCGAACGUGUCACGUTT

No.	shRNA Targets of RB1

siRNA-RB1-2	GGGUUGUGUCGAAAUUGGATT

s	GGAGUAU

No.	shRNA Targets of RB1

iRNA-RB1-4	GAUUCUAUUAUATT

Negative control siRNA (NC siRNA)	UUCUCCGAACGUGUCACGUTT


Module I: Basic concepts in global health

01.	Defining and measuring global health

02.	Global health definitions, case studies

03.	Historical origin and evolution

04.	Health systems and global health

Module II: Understanding the key global health challenges

01.	Current global health status

02.	Global burden of disease

03.	Global health priorities for twenty-first century

04.	Global health at the human–animal–ecosystem interface

Module III: Cross-cutting themes in global health and emerging trends

01.	Environment, climate, and migration

02.	Food, water, and sanitation

03.	Health disparities

04.	Women’s health

05.	Emerging, remerging infectious diseases

06.	NCD and injuries

07.	Maternal and child health

08.	Childhood immunization

09.	Adolescent health

10.	Neglected tropical diseases

11.	Antimicrobial resistance

Module IV: Global health diplomacy

01.	Overview of global health diplomacy

02.	Global health actors and activities

03.	Global health financing

04.	Global health policy and governance

05.	Drivers of policy for global health diplomacy

06.	Globalization, trade, work, and health

07.	Foreign policy and health

Module V: Global health security

01.	Global health security

02.	Pandemics and health security responses

03.	Health in complex humanitarian emergencies

04.	Humanitarian response and humanitarian dilemmas

05.	Global health equity

06.	Values in global health

07.	Toward a social justice approach to global health

Module VI: Research, development, innovation, and technology for global health

01.	The environment, sustainable development, and health

02.	Universal health coverage in the context of aging

03.	Sustaining good health with equity at low cost

04.	Science and technology for global health

05.	Scaling up effective models in global health delivery

Module I: Basic concepts in global health

02.	Global health actors and activities

03.	Global health financing

04.	Global health policy and governance

05.	Drivers of policy for global health diplomacy

06.	Globalization, trade, work, and health

07.	Foreign policy and health

Module V: Global health security

01.	Global health security

02.	Pandemics and health security responses

03.	Health in complex humanitarian emergencies

04.	Humanitarian response and humanitarian dilemmas

05.	Global health equity

06.	Values in global health

07.	Toward a social justice approach to global health

Module VI: Research, development, innovation, and technology for global health

01.	The environment, sustainable development, and health

02.	Universal health coverage in the context of aging

03.	Sustaining good health with equity at low cost

04.	Science and technology for global health

05.	Scaling up effective models in global health delivery


Questions	Partners	Regenstrief	Intermountain Health Care	Veterans' Health Administration

CIS modules offered (products that have capability to provide decision support)?	Yes, CPOE, results review, laboratory, outpatient clinical documentation, eMAR, Drug-Drug/Allergy/Lab Interaction checking. BCMA	Yes, CPOE, consults from specialists. Documentation: patient visit notes, ADT summaries, problem lists. Links to test results, notes	Yes, Antibiotic, TPN; Results review; RN, RT, Pharmacist charting; Infection & Disease monitoring, ADR triggers, VTE high risk alerts	Yes, Order menus, sets, quick orders. documentation. Templates. Drug-Drug/Allergy/Lab Interaction checking. BCMA

EHR delivery model?	Onsite	Onsite	Onsite (Server and web based)	Onsite (move to regional server)

CDS content implemented/configured/maintained by customer or vendor?	maintained by informaticians. Most content separate from code viewed thru repository	Clinician/Informaticians update terminology and decision support rules as needed	Users responsible for content. Programmers logic. Updated weekly, larger updates quarterly	CDS maintained, implemented locally. National releases with local configuration.

Collect structured data and which controlled vocabularies?	LOINC, RxNorm, SNOMED, ICD-9, CPT, FDB	ICD-9 & CPT codes avail. Most entered via Regenstrief Dict. mapped to standard vocabs.	Mostly coded data, some dictated notes as free text. LOINC, SNOMED, ICD-9	Not from clinician notes, but reminder templates do. ICD-9 for problem list

Support ad-hoc queries? Live replicating database?	Yes. Yes, weekly to monthly depending on data element	Queries done by data analysts on real database, in response to requests from end users.	Yes, but most reports run on EDW from programmers. Have some canned reports monthly	Yes, use replicated DB, varied update frequency; ProClarity data cubes

HL7 InfoButton?	Yes	No	Yes	No, but something similar

Arden Syntax for MLM?	No	No. Gopher Care Rules corresponds to Arden Syntax.	No (some graduate projects)	No

Clinical knowledge editor for user to create CDS?	Yes	Editor used by infomaticians to create CDS	Ability for knowledgeable users to create CDS	Not by end user. Some local configuration by support staff

Content mgmt system separate from EHR?	Yes	No	Online K repository, most review/updates programmers	No. Pilots are ongoing.

Reporting capability to track effect/usage of CDS content?	Yes	User responses prospectively, not retrospective	Yes, from reports in the EDW	Yes, focused on performance measures not CDS usage

Drug database supplier?	FDB	In-house drug terms	FDB	Internal Drug/Allergy files

3rd party CDS content vendors?	Thompson Micromedex, UpToDate	No	MicroMedex through Info-buttons	MicroMedex, UpToDate, etc. at point of care

Provide clinical content (starter sets). What content is included, how and how often and is it updated?	CDS content provided and maintained by the Informatics groups. Updates distributed on an as needed basis.	Alerts, drug-drug. Formulary, price. Order sets. Default drug strengths, frequencies, or instructions. updates mult/yr.	All alert logic is provided, developed, and maintained by institution. weekly and quarterly updates	Local development of reminders, order menus, document templates.

On-line collaborative knowledge development environment web 2.0?	Yes	No	No	Yes, starting SharePoint sites for national groups

Internet repository for clients to share locally generated CDS?	No	No	No	Some networks have web sites to share CDS


	H3K27me3	P value

Low	High	Total

pS9-GSK3β

 Low	13	10	23

 High	23	64	87

 Total	36	74	110

				0.006

	w		Total	 value

pS9-GSK3β

Low	13	10	23

High	23	64	87

Total	36	74	110

				0.006


	Model 1	Model 2	Model 3

Muscle Mass Index (abnormal versus normal)	1.113 (0.788–1.572)	1.190 (0.836–1.692)	1.42 (0.90–2.07)


Humans and Great Apes	All other mammals e.g. mouse	Peptide abbreviation	Gene name

Relaxin-1	Relaxin#	RLX1	RLN1

Relaxin-2#		RLX2	RLN2

Relaxin-3	Relaxin-3	RLX3	RLN3


Identifier	Best Arabidopsis match	Possible function	Position (kb)	Gene ID

C2H2 TF	AT3G18290	RING finger and CHY zinc finger encoding BRUTUS (BTS), E3 ligase protein with metal ion binding and DNA binding domains, which negatively regulates the response to iron deficiency	1,000	MDP0000283750

C2H2 TF	AT1G68360	C2H2 and C2HC zinc finger family	1,020	MPD0000183099

MdMYB7	AT1G68320	MYB involved in regulation of phosphate starvation responses and gibberellic acid biosynthesis.	1,070	MDP0000659260

bHLH	AT1G25330	bHLH75, BR enhanced	1,080	MDP0000725991

COL	AT1G68520	Contans-like light regulation of secondary metabolites	1,220	MDP0000185616

bZIP	AT1G68640	HBP-1b(c1), BZIP - PAN is essential for AG activation in early flowering	1,380	MDP0000250967

MdG2L6	AT1G25550	Golden-like ARR18 MYB-related	1,440	MDP0000202657

MdAP2D36 TF	AT1G68840	Regulator of vac ATPase Rav2 is part of a complex that has been named 'regulator of the (H+)-ATPase of the vacuolar and endosomal membranes' (RAVE)	1,480	MDP0000939633

LAR1		MdLAR1	1,540	MDP0000376284

bHLH	AT1G68810	Known bHLH, no other function	1,550	MDP0000319726

bHLH	AT1G68920	bHLH49 Known bHLH, no other function	1,890	MDP0000154272

MdbHLH21	AT1G69010	BES1-INTERACTING MYC-LIKE PROTEIN 2	1,970	MDP0000149222


Week	Weekly theme

1	Introduction and briefing on the aims of the rehabilitation program• Introduction to group• Introduction of the concept of self-efficacy• Information on post-stroke balance self-efficacy and rehabilitation

2	Understanding the relationships between thoughts, emotions, and behavior• Introduction to the CBT model• Understanding fear, fear of falling, fall risks, and actual falls• Understanding the automatic thoughts and emotional and behavioral reflection associated with fear of falling

3	Exploring thoughts and maladaptive responses• Identifying maladaptive thoughts leading to physical inactivity• Adapting realistic views of fall risk and the consequences of falls• Recognizing risky behavior• Overcoming barriers to physical activity

4	Exploring adaptive thoughts and behavioral responses• Fall prevention strategies and safety issues• Recognizing and minimizing fall risk

5	Implementing and reviewing behavioral changes related to ADL• Setting personal goals for ADL• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety

6	Implementing and reviewing behavioral changes related to social activities• Setting personal goals for social activities• Planning to achieve personal goals in small stages• Recognizing potential hazards and planning for safety

7	Reviewing and advancing individual therapeutic goals• Reviewing personal goals for ADL and social activities• Establishing a regular exercise plan

8	Consolidating the experiences of the rehabilitation program• Sharing attitudes and experiences of fear of falling before and after the group• Sharing experiences of applying cognitive-restructuring skills• Establishing the long-term personal goals of regular exercise, ADL independence, and social engagement


	Athletes	Controls	P‐values

Baseline characteristics

n	19	8

Age (year)	26 ± 5	31 ± 4	0.07

Height (m)	1.77 ± 0.08	1.80 ± 0.10	0.47

Body mass (kg)	72.6 ± 9.5	84.1 ± 12.2	0.02

Body mass index (kg/m2)	23 ± 2	26 ± 3	0.01

Maximal oxygen uptake (mL/kg·min−1)	55.9 ± 4.9	39.2 ± 5.0	<0.001

Resting values

n	19	8

Heart rate (bpm)	54 ± 8	58 ± 5	0.20

Mean arterial pressure (mmHg)	73 ± 10	74 ± 10	0.92

Middle cerebral artery mean blood velocity (cm/sec)	63.9 ± 11.7	65.5 ± 14.8	0.75

Cerebrovascular conductance index (cm sec−1 mmHg−1)	0.88 ± 0.14	0.91 ± 0.23	0.72

	Athletes	Controls

Baseline characteristics

n	19	8

Age (year)	26 ± 5	31 ± 4

Height (m)	1.77 ± 0.08	1.80 ± 0.10

Body mass (kg)	72.6 ± 9.5	84.1 ± 12.2

Body mass index (kg/m2)	23 ± 2	26 ± 3

Maximal oxygen uptake (mL/kg·min−1)	55.9 ± 4.9	39.2 ± 5.0

Resting values

n	19	8

Heart rate (bpm)	54 ± 8	58 ± 5

Mean arterial pressure (mmHg)	73 ± 10	74 ± 10

Middle cerebral artery mean blood velocity (cm/sec)	63.9 ± 11.7	65.5 ± 14.8

Cerebrovascular conductance index (cm sec−1 mmHg−1)	0.88 ± 0.14	0.91 ± 0.23

P‐values

Baseline characteristics

0.07

0.47

0.02

0.01

<0.001

Resting values

0.20

0.92

0.75

0.72


	Healthy (n = 18)	Post-OP (n = 28)	Sepsis (n = 15)

IL-6 (pg/ml)	0.0; 0.0–0.8	216.7; 48.8–360.5	577.7; 521.9–583.2

P-value	Healthy versus Post-OP: P < .001***

Healthy versus Sepsis: P < .001***

Post-OP versus Sepsis: P <.001***

TRX1 (ng/ml)	11.0; 10.0–12.1	11.3; 9.6–15.6	34.0; 19.7–57.7

P-value	Healthy versus Post-OP: P = .458

Healthy versus Sepsis: P < .001***

Post-OP versus Sepsis: P <.001***

MIF (pg/ml)	161.6; 148.5–214.0	156.4; 115.1–398.7	1821.1; 412.2–3708

P-value	Healthy versus Post-OP: P = .954

Healthy versus Sepsis: P = .005**

Post-OP versus Sepsis: P < .001***

	Healthy (n = 18)	Post-OP (n = 28)	Sepsis (n = 15)

P-value	Post-OP versus Sepsis: P <.001***

TRX1 (ng/ml)	11.0; 10.0–12.1	11.3; 9.6–15.6	34.0; 19.7–57.7

P-value	Healthy versus Post-OP: P = .458

Healthy versus Sepsis: P < .001***

Post-OP versus Sepsis: P <.001***

MIF (pg/ml)	161.6; 148.5–214.0	156.4; 115.1–398.7	1821.1; 412.2–3708

P-value	Healthy versus Post-OP: P = .954

Healthy versus Sepsis: P = .005**

Post-OP versus Sepsis: P < .001***


No.	Age	Sex	AQP1/4 tissue	Brief history	Probable cause/

 	(years)	 	immunoreactivity*	 	underlying cause of

 	 	 	 	 	CPM

1	56	M	0	Alcoholism; nausea and vomiting 1 week; hyponatremia, abnormal liver function tests; presented to Emergency Room in cardiorespiratory arrest.	Rapid correction of hyponatremia

2	53	M	0	Depression and chronic obstructive pulmonary disease. Not seen for 4 days; found dehydrated and malnourished; drug and alcohol screen negative.	Dehydration, malnutrition and hypernatremia

3	33	M	0	Cryptogenic cirrhosis with antitrypsin heterozygosity; orthotopic liver transplant and hyponatremia followed by progressive obtundation and seizures.	Orthotopic liver transplant

4	45	M	0	Small-cell lung carcinoma, metastatic to liver; abnormal liver function tests; possible malnutrition; hyperkalemia; several syncopal episodes in preceding hours; presented with respiratory failure.	SIAD secondary to small-cell lung carcinoma

5	24	F	↑	Hepatic failure and autoimmune thrombocytopenic purpura, 6 months; altered consciousness level and nonconvulsive status epilepticus 5 weeks before death; hypocalcemia, hyperammonemia and elevated liver enzymes.	Hepatic failure and hypocalcemia

6	68	F	↑	Hypertension, obesity, diabetes mellitus, hyperuricemia and remote endometrial carcinoma (treated by resection, chemotherapy, and radiotherapy); presented with gangrene of the right fifth toe; generalized seizure followed by unresponsiveness.	Diabetes mellitus type II

No.	Age	Sex	AQP1/4 tissue	Brief history

	(years)		immunoreactivity*

1	56	M	0	Alcoholism; nausea and vomiting 1 week; hyponatremia, abnormal liver function tests; presented to Emergency Room in cardiorespiratory arrest.

2	53	M	0	Depression and chronic obstructive pulmonary disease. Not seen for 4 days; found dehydrated and malnourished; drug and alcohol screen negative.

3	33	M	0	Cryptogenic cirrhosis with antitrypsin heterozygosity; orthotopic liver transplant and hyponatremia followed by progressive obtundation and seizures.

4	45	M	0	Small-cell lung carcinoma, metastatic to liver; abnormal liver function tests; possible malnutrition; hyperkalemia; several syncopal episodes in preceding hours; presented with respiratory failure.

5	24	F	↑	Hepatic failure and autoimmune thrombocytopenic purpura, 6 months; altered consciousness level and nonconvulsive status epilepticus 5 weeks before death; hypocalcemia, hyperammonemia and elevated liver enzymes.

6	68	F	↑	Hypertension, obesity, diabetes mellitus, hyperuricemia and remote endometrial carcinoma (treated by resection, chemotherapy, and radiotherapy); presented with gangrene of the right fifth toe; generalized seizure followed by unresponsiveness.

Probable cause/

underlying cause of

CPM

Rapid correction of hyponatremia

Dehydration, malnutrition and hypernatremia

Orthotopic liver transplant

SIAD secondary to small-cell lung carcinoma

Hepatic failure and hypocalcemia

Diabetes mellitus type II


Health risk behavior	Men	Women

	N	(%)	N	(%)

Current smoking	10784	(57.3)	3099	(15.6)

Excess alcohol consumption	5177	(27.4)	1155	(5.8)

Physical inactivity	13989	(71.2)	14926	(72.0)

Poor dietary habits	7974	(40.6)	5671	(27.4)

Stress	9639	(51.9)	12151	(61.3)

Non-attendance of health check-ups	5243	(27.5)	8532	(42.3)

Health risk behavior	Men	Women

	N	(%)	N	(%)

Current smoking	10784	(57.3)	3099	(15.6)

	5177		115	(5

Health risk behavior	Men	Women

	N	(%)	N	(%)

Excess alcohol consumption		(27.4)	5	.8)

Physical inactivity	13989	(71.2)	14926	(72.0)

Poor dietary habits	7974	(40.6)	5671	(27.4)

Stress	9639	(51.9)	12151	(61.3)

Non-attendance of health check-ups	5243	(27.5)	8532	(42.3)


			Microaerobic culture

			+	-	Total

4.1 Campylobacter coli detection in faecal samples		+	125	1	126

	Real-time PCR	-	3	17	20

		Total	128	18	146

4.2 Campylobacter coli detection in feed samples		+	21	1	22

	Real-time PCR	-	2	26	28

		Total	23	27	50

4.3 Campylobacter coli detection in environmental samples		+	34	2	36

	Real-time PCR	-	3	47	50

		Total	37	49	86

			Microaerobic culture

			+	-	Total

	Real-time PCR	-	3	47	50

		Total	37	49	86


Sequences	Descent	Ascent	Stop (Life Bases)	P

n	%	n	%	n	%

Feeling pain (FP)	10	31.2	14	43.8	8	25	0.4633

Putting meaning to those feelings (PM)	5	17.8	16	57.2	7	25	0.0269 *

Adjusting running style (AR)	6	40	7	46.6	2	13.4	0.3593

Attempting to overcome the problem (OP)	0	0	0	0	7	100	0.0009 *

Influence of other runners (IR)	0	0	5	23.8	16	76.2	0.0005 *

Assessing the overall situation (AS)	3	10.3	5	17.3	21	74.4	0.0005 *

Total	24	18.2	47	35.6	61	46.2	0.0003 *

Sequences	Descent	Ascent	Stop (Life Bases)	P

n	%	n	%	n	%

Total	24	18.2	47	35.6	61	46.2	0.0003 *


Variable	Numberb	Percent

Pregnancy	1st trimester	710	18.40


Precursor	Bond length in precursor (Å)	Bond length in transition state structures (Å)

M-S bond a	C-S bond	M-S bond a	C-S bond	C-N bond	N-H bond b

Ag(SCO	2.		2.39	2	1.60	1.061


	Number	Incidence (%)	Anomalies (%)

Benign anomalies

CA from RCS	8	1.07	24.24

Absence of LMA	7	0.93	21.21

Posterior RCA	1	0.13	3.03

Potentially clinically significant anomalies

Superior RCA	7	0.93	21.21

CFX from RCS	4	0.53	12.12

CFX from RCA	2	0.26	6.06

Coronary fistula	1	0.13	3.03

Coronary aneurysm	1	0.13	3.03


Metric	Value

Families making <Q 2000a per month	66 %

Families making Q 2000–4000a per month	34 %

Average persons per household	6.4

Average children per household	3.3


	Study 1	Study 2

Age, y	24 ± 4	26 ± 3

Body mass, kg	72.9 ± 3.9	65.8 ± 9.0

Height, m	1.70 ± 0.09	1.70 ± 0.10

BMI, kg/m2	25.0 ± 1.1	22.8 ± 0.9

Body fat, kg	24.2 ± 11.4	19.3 ± 3.7

Body fat, %	32.4 ± 2.0	29.8 ± 6.5

Lean mass, kg	45.3 ± 8.1	43.6 ± 8.7

Peak bike power, watts	n/a	145 ± 43

Peak VO2, mL/kg/min	n/a	26.4 ± 5.9

Peak heart rate, beats/min	n/a	179 ± 15

Total cholesterol, mmol/L	3.98 ± 0.99	4.03 ± 0.90

HDL cholesterol, mmol/L	1.21 ± 0.37	1.11 ± 0.33

Triglycerides, mmol/L	0.74 ± 0.39	0.89 ± 0.31

C-reactive protein, nmol/L	18.4 ± 19.9	11.0 ± 5.2

Glucose, mmol/L	4.7 ± 0.2	4.8 ± 0.5

Insulin, pmol/L	41 ± 28	41 ± 27

Systolic blood pressure, mmHg	109 ± 9	112 ± 10

Diastolic blood pressure, mmHg	68 ± 8	62 ± 7

	Study 1	Study 2

C-reactive protein, nmol/L	18.4 ± 19.9	11.0 ± 5.2

Glucose, mmol/L	4.7 ± 0.2	4.8 ± 0.5

Insulin, pmol/L	41 ± 28	41 ± 27

Systolic blood pressure, mmHg	109 ± 9	112 ± 10

Diastolic blood pressure, mmHg	68 ± 8	62 ± 7


Compound	LOD (μg/L)	LOQ (μg/L)	RSD (%)	Recovery (%)	Method	References

Caffeine	3610	10,940	1.7	95 ± 7	HPLC–DAD–MS	[4]

Theobromine	30	100	6.5	97 ± 3

Trigonelline	3770	11,420	1.0	102 ± 2

Caffeine	80	–	0.20–6.2	99 ± 3	HPLC–UV	[9]

Theobromine	140	2.8–9.1	103 ± 6

Trigonelline	260	1.1–5.0	99 ± 5

Caffeine	11.9	39.6	2.1–4.7	97 ± 4	LC–MS	[12]

Theobromine	–	–	–	–

Trigonelline	36.4	121.5	3.2–3.5	140 ± 16

Caffeine	2	40	3	99 ± 2	Fluorescence	This study

Theobromine	6	20	3	–

Trigonelline	7	20	4	99 ± 2


Inclusion Criteria	Exclusion Criteria

◆ Student at Haskell Indian Nations University◆ Age at least 18 years or older◆ Have a valid college/university email address, telephone number, and home address◆ Willing to participate in all study components◆ Willing to be followed-up over several years (1-4 years, depending on freshman cohort year)	◆ Planning to leave or graduate from the University before the end of the current academic year◆ Unable to participate in all components of the study


Vasectomy technique	Early recanalization	Vasectomy outcome	Total

		Failurea n (%)	Successb n (%)	Indeterminatec n (%)


Time interval(months)	Primary endpoint*	ARR(%)	RRR[95% CIs] (%)	NNT(per month)

Clopidogrel(%)	Placebo(%)

6–9	1.3	1.4	0.1	6 [–34, 34]	3171

9–12	1.1	1.3	0.2	14 [−32, 44]	1600

0–12	10.3	12.6	2.4	19	507

CHARISMA trial

0–28	6.8	7.3	0.5	7*	5591

Subgroup of patients with clinically evident atherosclerotic disease

0–28‡	6.9	7.9	1.0	12	2800


	Food-specific decentering	Awareness of food thoughts	Meditation experience

Food cravings	−0.62a	0.27	−0.47 a

Food-specific decentering		−0.29	0.25

Awareness of food thoughts			−0.20


High School/GED			.26(.06, 1.06)

Some College or more			1.76(.63, 4.89)


MolNo.	R1	R2	Predicted activity	Lipinski’s scoreandScreen

R-1	4-nitrophenyl	4-methoxyphenyl	0.8564	ADRXWS (6)

R-2	4-nitrophenyl	4-nitrophenyl	-0.3876	ADRXWS (6)

R-3	Benzyl	4-hydroxyphenyl	0.9765	ADRXWS (6)

R-4	3-aminophenyl	4-nitrophenyl	0.8450	ADRXWS (6)

MolNo.	R1	R2	Predicted activity	Lipinski’s scoreandScreen

R-1	4-nitrophenyl	4-methoxyphenyl	0.8564	ADRXWS (6)

R-2	4-nitrop	4-nitrophen	-0.387	ADR

	henyl	yl	6	XWS (6)

R-3	Benzyl	4-hydroxyphenyl	0.9765	ADRXWS (6)

R-4	3-aminophenyl	4-nitrophenyl	0.8450	ADRXWS (6)


Percent of invaded area	Himalayan blackberry	English ivy

In clusters	98.5	99.3

In outliers	1.5	0.7

Percent of invaded area

In clusters

In outliers

Himalayan blackberry	English ivy

98.5	99.3

1.5	0.7


		MB	no-MB

		Pre- trainin	Post-	Pre- 	Post


KDQOL-36TM Subscales	Mean	SD	Minimal (Floor%)	Maximal (Ceiling%)

Symptoms/problems list	74.22	15.24	37.50 (1)	100 (2.9)

Effects of kidney disease	54.78	20.10	00.00 (1)	96.88 (1)

Burden of kidney disease	33.07	23.31	00.00 (13.6)	100 (1)

Physical Composite Sore	36.60	7.83	17.05 (1)	54.92 (1)

Mental Composite Score	46.82	9.81	22.17 (1)	65.09 (1)

KDQOL-36TM Subscales	Mean	SD	Minimal (Floor%)	Maximal (Ceiling%)

Burden of kidney disease	33.07	23.31	00.00 (13.6)	100 (1)

Physical Composite Sore	36.60	7.83	17.05 (1)	54.92 (1)

Mental Composite Score	46.82	9.81	22.17 (1)	65.09 (1)


Comparison (5-Aza)	Methods	Cuffdiff

5 μM vs 0 μM	T-test	25.8%

	SAM	39.9%

	Ebayes	39.5%

10 μM vs 5 μM	T-test	0.5%

	SAM	31.1%

	Ebayes	30.3%


	Local density	Coeff. variation nearest distances	Area

Local density	1.00	---	---

Coeff. Variation nearest distances	0.22*	1.00	---

Area	-0.10	0.11	1.00

	Local density	Coeff. variation nearest distances	Area

Coeff. Variation nearest distances	0.22*	1.00	---

Area	-0.10	0.11	1.00


Variable	Factor	P value	HR	95.0% CI

Age	Continuous	0.367	1.02	0.98–1.05

Sex	Male	0.001	0.36	0.20–0.66

ECOG-PS	>1	0.034	2.13	1.06–3.39

Comorbidities (CVD or DM)	Positive	0.084	0.53	0.25–1.07

Metastatic disease	Positive	<0.001	9.34	5.12–17.1

Frailty discriminant score	>2.30	0.005	3.03	1.41–5.51

Variable	Factor	P value

Age	Continuous	0.367

Sex	Male	0.001

ECOG-PS	>1	0.034

Comorbidities (CVD or DM)	Positive	0.084

Metastatic disease	Positive	<0.001

Frailty discriminant score	>2.30	0.005


miRNA	Target	Effector cell	Affected chemokine	Role in atherosclerosis	References

miR-181b	Importin-α3	ECs	CXCL1	Protective	[58]

miR-103	KLF4	ECs	CXCL1CCL2	Damaging	Unpublished

miR-126-3p	RGS16	ECs	CXCL12	Protective	[64]

miR-10a	TAK1, β‐TRC	ECs	CCL2	Protective	[87]

miR-92a	KLF2, KLF4, SOCS5	ECs	CCL2CXCL1?	Damaging	[88]

miR-21	PPARα	ECs	CCL2	Damaging	[79]

let-7g	THBS1, TGFBR1, SMAD2	ECs	CCL2	Protective	[97]

miR-155	BCL6	Macrophages	CCL2	Damaging	[43]

miR-342-5p	AKT1	Macrophages	CCL2 (via miR-155)	Damaging	[102]

miR-467b	LPL	Macrophages	CCL2	Protective	[105]

miR-24	CHI3L1	Macrophages	CCL2	Protective	[108]

miRNA	Target	Effector cell	Affected chemokine	Role in atherosclerosis	References

miR-103	KLF4	ECs	CXCL1CCL2	Damaging	Unpublished

miR-126-3p	RGS16	ECs	CXCL12	Protective	[64]

miR-10a	TAK1, β‐TRC	ECs	CCL2	Protective	[87]

miR-92a	KLF2, KLF4, SOCS5	ECs	CCL2CXCL1?	Damaging	[88]

miR-21	PPARα	ECs	CCL2	Damaging	[79]

let-7g	THBS1, TGFBR1, SMAD2	ECs	CCL2	Protective	[97]

miR-155	BCL6	Macrophages	CCL2	Damaging	[43]

miR-342-5p	AKT1	Macrophages	CCL2 (via miR-155)	Damaging	[102]

miR-467b	LPL	Macrophages	CCL2	Protective	[105]

miR-24	CHI3L1	Macrophages	CCL2	Protective	[108]


	STIB900-M vs. STIB900	STIB900-P vs. STIB900

Overall	CDS	NS	Overall	CDS	NS

Chr1	0	0	0	2	0	0

Chr2	0	0	0	0	0	0

Chr3	0	0	0	1	0	0

Chr4	0	0	0	0	0	0


	Groups

	NH	CI

	Long, complex sentences	Highly meaningful sentences	Nonsense sentences	Long, complex sentences	Highly meaningful sentences	Nonsense sentences

Verbal Working Memory

LSpan (total letters correctly recalled)	.10	.05	.07	.64**	.57**	.68**

Rspan (total letters correctly recalled)	‐.01	.06	.13	‐.03	.01	‐.02

Modality‐General Neurocognitive Scores

Attention Sustained (scaled score)	.14	.07	‐.08	.14	.19	.29

Forward Memory (scaled score)	‐.10	‐.35	.17	.23	.23	.14

Reverse Memory (scaled score)	.06	‐.11	.08	.20	.20	.04

Verbal Stroop–Congruent (response time)	‐.04	.20	.07	‐.28	‐.29	‐.36

Verbal Stroop–Incongruent (response time)	‐.14	‐.05	‐.03	‐.41*	‐.43*	‐.43*

* p‐value < 0.05

** p‐value < 0.01CI = cochlear impant; LSpan = Listening Span; NH = normal hearing; RSpan = Reading Span

	Groups

	NH

	Long, complex sentences

Verbal Working Memory

LSpan (total letters correctly recalled)	.10

Rspan (total letters correctly recalled)	‐.01

Modality‐General Neurocognitive Scores

Attention Sustained (scaled score)	.14

Forward Memory (scaled score)	‐.10

Reverse Memory (scaled score)	.06

Verbal Stroop–Congruent (response time)	‐.04

Verbal Stroop–Incongruent (response time)	‐.14

* p‐value < 0.05

** p‐value < 0.01CI = cochlear impant; LSpan = Listening Span; NH = normal hearing; RSpan = Reading Span

Groups

NH	CI

Highly meaningful sentences	Nonsense sentences	Long, complex sentences	Highly meaningful sentences	Nonsense sentences

.05	.07	.64**	.57**	.68**

.06	.13	‐.03	.01	‐.02

.07	‐.08	.14	.19	.29

‐.35	.17	.23	.23	.14

‐.11	.08	.20	.20	.04

.20	.07	‐.28	‐.29	‐.36

‐.05	‐.03	‐.41*	‐.43*	‐.43*


Parameters	No of patients with ≥ G2 RP (%)

Age

< 75 years old	1 (11)

≥ 75	8 (89)

Sex

Man	6 (67)

Female	3 (33)

PS

0 or 1	8 (89)

2	1 (11)

Location of primary tumor

Upper or Middle lobe	7 (78)

Lower lobe	2 (22)

Clinical Stage

II	5 (56)

III	4 (44)

Total dose

≤ 72 Gy RBE	8 (89)

> 72 Gy RBE	1 (11)

Chemotherapy

Yes	0

No	9 (100)

Brinkman Index

< 600	3 (33)

≥ 600	6 (67)

Pulmonary emphysema

Yes	0

No	9 (100)


Dose (mg/cm2)	#	Mortality record for applied pests

		Record after 24 hours	Average ± SD record after 24 hours	Record after 48 hours	Average ± SD record after 48 hours

1.77	10	10	9.66 ± 0.57	10	9.66 ± 0.57


Variables	Unstandardised coefficients (B)	S.E	Standardised coefficients (Beta)	P value

Age	− 0.020	0.017	− 0.066	0.241

Marital status	0.052	0.041	0.077	0.205

Income level	0.064	0.023	0.163	0.006

The current condition	− 0.023	0.019	− 0.074	0.222

Pain severity score	− 0.011	0.002	− 0.353	< 0.001

Pain interference score	− 0.007	0.001	− 0.350	< 0.001

Post-treatment pain	− 0.010	0.051	− 0.012	0.842

Variables	Unstandardised coefficients (B)	S.E	Standardised coefficients (Beta)	P value

Pain severity score	− 0.011	0.002	− 0.353	< 0.001

Pain interference score	− 0.007	0.001	− 0.350	< 0.001

Post-treatment pain	− 0.010	0.051	− 0.012	0.842


		Selection		Comparability		Outcome assessment

Author	Year	1	2	3	4	5	6	7	Score

Kon	2007	*	*	*	*	**	*	-	*******